COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes

2	and finding signals of efficacy.
3	
4	Daniele Focosi ^{1,#}
5	Massimo Franchini ²
6	Liise-anne Pirofski ³
7	Thierry Burnouf ⁴
8	Nigel Paneth ⁵
9	Michael J. Joyner ⁶
LO	Arturo Casadevall ⁷
L1	
L2	¹ North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
L3	² Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy;
L4	massimo.franchini@asst-mantova.it
L5 L6	³ Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY 10467, USA; l.pirofski@einsteinmed.org
17 18 19	⁴ Graduate Institute of Biomedical Materials and Tissue Engineering & International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; thetatauto.com (International PhD Program in Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; thetatauto.com (International PhD Program in Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; thetatauto.com (International PhD Program in Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; thetatauto.com (International PhD Program in Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; thetatauto.com (International PhD Program in Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; thetatauto.com (International PhD Program in Biomedical Engineering) (International PhD Program
20 21	⁵ Departments of Epidemiology & Biostatistics and Pediatrics & Human Development, College of Human Medicine, Michigan State University, East Lansing, MI 48824, paneth@msu.edu
22	⁶ Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA;
23	joyner.michael@mayo.edu
24 25	⁷ Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore, MD, USA; <u>acasade1@jhu.edu</u>
26	
27	#corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail: daniele.focosi@gmail.com
28	
29	Word count: abstract 283; body 5835.

- 30 **Keywords**: COVID-19; convalescent plasma; randomized clinical trial; propensity score-matched;
- 31 neutralizing antibodies; viral neutralization tests.

- 32 **Abbreviations**: BSC : best supportive care; CP : convalescent plasma; CCP : COVID-19
- convalescent plasma; nAbs: neutralizing antibodies; VNT: viral neutralization test;
- 34 **Author contributions**: D.F. designed the paper, analyzed the data, and wrote the first draft. M.F.,
- 35 M.J.J., T.B., L.P., N.P. and A.C. revised the manuscript. All authors approved the final version.

Abstract

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is available as soon as there are survivors. The COVID-19 pandemic represented the first large-scale opportunity to shed light into mechanisms of action, safety and efficacy of CP using modern evidence-based medicine approaches. Studies ranging from observational case series to randomized controlled trials (RCT) have reported highly variable efficacy results for COVID-19 CP (CCP), resulting in uncertainty. Reasons for CCP success and failure may be hidden in study details, which are usually difficult to explain to physicians and the public but provide fertile ground for designing next-generation studies. In this paper-We analyzed variables associated with efficacy such as clinical settings, disease severity, CCP SARS-CoV-2 antibody levels and function, dose, timing of administration (variously defined as time from onset of symptoms, molecular diagnosis, diagnosis of pneumonia, or hospitalization, or by serostatus), outcomes (defined as hospitalization, requirement for ventilation, clinical improvement or mortality), CCP provenance and time for collection, and criteria for efficacy. Focusing only on the results from the 30 available RCTs we noted that these were more likely to show signals of efficacy, including reductions in mortality, if the plasma neutralizing titer was ≥ 160 and the time to randomization was ≤ 9 days, consistent with passive antibody therapy efficacy requiring dosing with sufficient antibody. The fact that most studies revealed signals of efficacy despite variability in CCP and its use suggest likely therapeutic effects that become apparent despite the data noise. Despite the recent WHO guidelines discouraging CCP usage, the Omicron variant of concern is reminding us the superiority of polyclonal antibody therapies over monoclonal antibodies, and CCP from vaccinated convalescents is to be evaluated likely soon Table of contents

60	Introduction	4
61	Methods	5
62	Results	6
63	The indication	6
64	The therapeutic dose	7
65	Relevance of CCP to the viral variant	.10
66	The intended outcomes	.11
67	Analyzing conflicting outcomes in individual RCTs.	.12
68	The inadequacy of meta-analyses.	.14
69	Recommendations	.17
70	The future of CCP	.18
71	Figure 1	.20
72	Figure 2	.22
73	Table 1	.24
74	Table 2	.29
75	Table 3	.39
76	Table 4	.42
77	References	.44

Introduction

In the first 21 years of the 21st century humanity has experienced six major multinational epidemics. The agents involved were SARS-CoV, MERS-CoV, influenza A(H₁N₁), Ebola, Zika and SARS-CoV-2 viruses. For the five most lethal of these outbreaks the response included the use of convalescent plasma (CP) (reviewed in (1, 2)) and it was considered for the less lethal sixth (Zika virus). The attraction of CP is that it is readily available as soon as there are convalescing survivors, that unlike drugs or monoclonal antibodies it needs no development, and it is polyclonal, affordable and deployable even in resource poor countries. Despite suffering from some logistical hurdles (dedicated collection, testing and handling procedures, heterogeneity, standardization of the therapeutic dose, blood type matching, and intravenous delivery), CP has been proposed as a first line response to new pandemics (3) and was deployed during the COVID-19 pandemic in March 2020 in countries that experienced the early waves of disease such as China (4, 5) and Italy (6). The relatively low COVID-19 case-fatality rate (compared to the other epidemic agents noted above) allowed for testing of CP across a wider spectrum of disease severity.

While in early 2020 most clinical use was reported in case series or small phase II clinical trials (7), beginning in late March 2020 the US expanded access program (EAP) generated a large and robust treatment dataset, with insights on safety and optimal use. This database provided the first clear evidence that CP is safe, which was important given that early in the pandemic there were significant concerns about antibody-dependent enhancement (8). Later, an analysis of the first 3082 patents within the EAP database provided evidence that associated early administration of high titer CCP to non-ventilated hospitalized patients with reduced mortality (9). Before the FDA granted emergency use authorization (EUA), the US EAP provided CCP to as many as 94,287 patients.

During the past year, many studies employing either randomized controls (RCT) or propensity score-matched (PSM) controls have been published. RCTs and PSM studies reported so far have had largely opposite outcomes, with most but not all RCTs finding little overall effect on mortality while the PSM and many smaller trials reporting mortality benefits. Several RCTs did not have mortality as a primary endpoint or it was part of a composite endpoint (5, 10-12). These disparate results have led to confusion for both the public and the clinicians, leading to reduced enthusiasm for the use of CP, in part because RCT data is more influential in affecting the opinion of many physicians, specialty societies and government regulators.

As with any other medical treatment, several key factors should be taken into account when evaluating a trial, including the indication (which can be estimated by timing or clinical severity), the therapeutic dose and the intended outcomes. The choices made by the trial designers determine whether the trial will demonstrate clinical benefit. While much attention is appropriately focused on the performance features of clinical trials (sample size, fidelity to randomization, appropriate analysis), the biological rationale for the hypothesis being tested is critically important but not always taken into account.

Methods

- On December 13, 2021, we searched PubMed (which is also indexing the medRxiv prepublishing server) for clinical trials of CCP in COVID19, focusing on RCTs and PSM studies only. Each study was analyzed for the following variables: NCT identifier, recruitment, randomization strategy, type of control arm, baseline patient status, median neutralizing antibody (nAb) titer in both recipients (before CCP transfusion) and CCP units, type of viral neutralization test (VNT), primary endpoint, signals of efficacy, and reasons for failure
- At the same date, the ClinicalTrials.gov database was searched for CCP RCTs worldwide having as status "completed", "active, not yet recruiting" or "recruiting".

Results

127

134 135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

- 128 PubMed search retrieved 28 RCTs and 13 PSM studies about CCP, whose main variables are
- 129 summarized in Tables 2 and 3. The characteristics of the VNTs used are summarized in Table 1. The
- variables were reconciled in 4 major topics, discussed in the following sections: the indication, the
- therapeutic doses, the relevance of CCP to the viral variant, and the intended outcome.
- 132 ClinicalTrials.gov search retrieved 7 CCP RCTs completed but not yet prepublished or published, 5
- active but not yet recruiting RCTs, and 12 RCTs which are still recruiting (summarized in Table 4).

The indication

While it would be desirable to have a single drug that works at any disease stage, it was not reasonable to expect neutralizing antibody (nAb)-based treatments such as CCP to have a significant effect in later stages of disease. COVID-19 is now well-defined as a disease with two stages, an initial viral phase characterized by flu-like and upper and lower respiratory symptoms, followed, in severe cases, by an inflammatory phase that is characterized by inflammation-driven damage to multiple organ systems, including the lungs that can impair gas exchange and cause life-threatening hypoxia and damage to multiple organs, including the brain and blood vessels (13). Accordingly, lack of endogenous nAb at baseline has been associated with a higher risk of viremia, but Marconato et al showed that CCP recipients benefit from high-titer CCP even after adjusting for their endogenous nAb (14). Specific intact antibodies in CCP are expected to neutralize SARS-CoV-2 in the intravascular system and, in some patients, prevent progression from early to severe and life-threatening disease (as seen in animal models (15-17)). However, this antiviral therapy cannot be expected to reverse the inflammatory phase of the disease, nor neutralize infectious viruses invading the extravascular system. Thus, COVID-19 is similar to influenza, a disease in which antivirals are effective early in disease but have no effect in later stages when the symptomatology stems largely from the inflammatory response. The rationale for administering CCP as early as possible in the course of COVID-19 stems from the neutralization stoichiometry itself: the larger the number of actively replicating virions in the body, the higher the nAb dose needed for neutralization (18). Some uncontrolled studies have reported a lack of association between early intervention and outcomes (19, 20), but in these studies the level of nAb or the overall anti-Spike antibody level in the infused CCP was unknown, leaving room for alternative explanations.

At the beginning of the pandemic, some investigators and opinion leaders, riding the wave of CCP successes in anecdotal reports in the media and small case series, introduced CCP to the general public as a panacea for any patient with COVID-19, including life-threatening cases, leading to confusing messaging: after reports of failure in severely ill patients emerged, opinions became polarized and the debate became anything but scientific (21). In clinical trials, the indication (i.e., the baseline clinical setting) has been variously defined by patient status (outpatient vs. presenting to the emergency room vs. hospitalized vs. ICU-admitted), disease severity (using 5-category COVID-19 Outpatient Ordinal Outcome Scale (22), a 6-category ordinal scale (12), a 7-category COVID-19 severity scale (23), the WHO 8- (24) or 11-category (25) ordinal scales, or pneumological scores such as SOFA), the time elapsed before recruitment (also variably defined as from molecular diagnosis,

from onset of hospitalization, from diagnosis of pneumonia, or from onset of symptoms), or by serological status (presence of antibodies or the ability to neutralize SARS-CoV-2). This variability in inclusion criteria for studies has resulted in marked heterogeneity in recruited patients. As shown by CONTAIN (where those with shorter of symptom durations did worse), symptom duration can a poor indicator of 'early' disease but actually an indication of severe, rapidly progressive disease (26). Disease severity marked by WHO score as opposed to symptom duration may be a more accurate tool to capture "early" disease, as supported by the positive results with CCP in low WHO scores summarized in Figure 1.

The vast majority of SARS-CoV-2 infections are mildly symptomatic, so when dealing with outpatients (WHO categories 1 to 3; the strata which are most likely to benefit from nAb-based therapies), the number needed to treat (NNTT) in order to prevent a single hospitalization or death can be very large, and even larger if vaccinees are recruited. In order to be economically and logistically sustainable, it seems wise to focus on those outpatients having risk factors for disease progression, as done with COVID19 mAbs. This approach was pursued by C3PO (27) and NCT04479163, but not other outpatient RCTs (COV-Early (28), CSSC-004 (29)). A special category is represented by outpatients recruited at the time of ER attendance (e.g. in C3PO (27): they should be considered at the border between outpatients and inpatients, and hence not aggregated in outpatient metanalyses. Among outpatients not recruited at the ER, clinical benefit has been shown up to 6 days since onset of symptoms (e.g. in the CSSC-004 RCT (29)). No benefit of CCP over FFP has been proven in the single RCT of post-exposure prophylaxis (CSSC-001) at preventing infection, symptomatic disease, but the study was not powered to detect a reduction in hospitalization (30).

For what concerns inpatients (WHO categories 4 to 9), clinical benefit from antivirals can only be expected for categories 4 and 5, since from category 6 on the patients require high-flow oxygen and hence have significant respiratory failure.

The therapeutic dose

Determining the effective dose of CCP is difficult in a pandemic because the antibody assays and other tests needed to assess the potency of any antibody product take time to be developed. In practice, the effective dose is the product of multiple factors, none of which is fully standardized.

The first factor is the concentration of the nAbs as measured by a viral neutralization test (VNT). At the beginning of the pandemic, only a few biosafety level 3 (BSL3) (or higher)-equipped virology laboratories could run VNT using authentic live SARS-CoV-2 virus: the procedure was time-consuming (3-5 days) and the reports were operator-dependent. Nowadays, the availability of Spike-pseudotyped viruses which can be managed under the more widely available BSL-2 laboratories, or cell-free ACE-2 competition assays, combined with automated (e.g., luminescence-based) readings, have standardized outcomes and shortened turnaround times (31): however, harmonization between different assays is still a work in progress (32). The VNT differs according to the type of replication-competent cell line, the viral isolate used for the challenge (which is critically important when the virus

is mutating rapidly as has been the case with emergence of variants of concern), the multiplicity of infection (i.e., the ratio between the viral inoculum - referred with different measuring units - and the number of replication-competent cells within each well), the detection system (optic microscopy for cytopathic effect, immunostaining, quantitative PCR, or luminometer for engineered pseudoviruses), and finally the threshold of neutralization (50% or 90%). The DAWN-plasma (33), C3PO (27), and REMAP-CAP (34) RCTs provide clear examples of such heterogeneity, with up to 4 different VNTs used at different participating laboratories/countries within the same study (see Table 1). It was not until August 2020, when many trials were already underway, that the FDA Emergency Use Authorization 26382 defined high-titer CCP on the basis of correlation with a reference standard, the Broad Institute live-virus, 5-dilution VNT as a 50% inhibitory dilution (ID₅₀) of 1:250 or more (https://www.fda.gov/media/141481/download), and exclusive use of high-titer CCP was formally recommended by the FDA only on March 9, 2021. Table 1 summarizes the key variables in VNT employed to date in CCP RCTs. Published trials have varied greatly in their approaches to antibody quantification whether in measured transfused CCP units or in recipients. Several RCTs performed nAb titration, but with highly heterogenous methods which makes comparability of doses across studies difficult. Table 1 attempts to reconcile doses across those trials, showing that they actually differed more than is apparent by inspection of raw titers.

Despite these uncertainties, we can make estimates of likely effective doses based on the available clinical experience thus far. The lack of utility from low-titer (1:40) CCP in moderate COVID-19 was confirmed by the PLACID trial (10). As long as a clear therapeutic dose is not identified, it seems prudent to transfuse units containing nAb titers at least 10-fold higher than the nAb titer measured before transfusion in recipient serum. Similarly, the ConCOVID RCT showed that CCP units having nAb titers similar to those of the recipients (1:160) did not confer a clinical benefit (35). CCP units with an adequate nAb titer (nowadays estimated at ≥1:160) are more easily found among older males who recovered from a previous symptomatic COVID-19 requiring hospitalization (36, 37): unfortunately, such donors were poorly represented in the first donation waves, which tended to obtain CCP from younger donors will mild disease, and, presumably lower nAb titers (10).

Many trials have relied on high-throughput semi-quantitative or qualitative assays with a poor-to-moderate relationship with nAb titers. Harmonization of such high-throughput assays using the WHO International Standard of binding arbitray units (BAU) is nowadays possible (38). Although most trials performed a correlation analysis between VNT and high-throughput serological assays, in many cases the CCP units were tested only with the latter without validation, as was the case with 66% of the patients in the PlasmAR trial (12). This procedure risks an incorrect evaluation of the neutralizing CCP activity. Another cause for discrepancies in outcomes could be that although IgM, IgG, and IgA are all capable of mediating neutralization, VNT titers correlate better with binding levels of IgM and IgA₁ than they do with IgG (39). By contrast, routinely used high-throughput serological assays only quantify IgG, including non-neutralizing IgGs, whose potency against SARS-CoV-2 has not been established. Trials should preferentially use VNTs to assess serostatus of transfused units and not rely on high-throughput serology. As for any other medicinal product, CCP exhibits a dose-response

relationship, which is also evident when using high-throughput assays. In the subgroup analysis of the EAP, a gradient of mortality was seen in relation to IgG antibody levels in the transfused CCP. In the subgroup of patients who were not receiving mechanical ventilation, death within 30 days after CCP transfusion occurred in 81 of 365 patients (22.2%; 95% CI, 18.2 to 26.7) in the low titer group, 251 of 1297 patients (19.4%; 95% CI, 17.3 to 21.6) in the medium-titer group, and 50 of 352 patients (14.2%; 95% CI, 10.9 to 18.2) in the high-titer group. Depending on the statistical model, the RR for 30-day mortality in high-titer CCP compared to low-titer CCP recipients ranged from 0.64 – 0.67, with an upper 95% confidence bound of 0.91 (8). Similarly, the large retrospective PSM study from Hospital Corporation of America (HCA) Healthcare-affiliated hospitals reported a 0.2% decreased risk of mortality for every 1 unit of S/Co serology level (40).

An additional limit is testing nAbs only at the time of first donation (e.g., in ConCOVID (35)) while leaving donors opportunities to repeat donation for months: given the expected decline of nAb levels in time in convalescents, this could have overestimated the actual dose.

The nAb titer (or total IgG levels as measured by surrogate assays) only describes one factor involved in defining the real therapeutic dose in that it represents the concentration of just one (likely the main) active ingredient. But CCP contains additional antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC), complement activation and phagocytosis of viral particles, functions that can each contribute to its antiviral effects (41). At this time the relative importance of nAbs vs. the other antibody activities is not understood, but, hopefully, retrospective analyses that correlate CCP efficacy with these activities will reveal additional variables that need to be considered in choosing optimal CCP units. This has relevance when assessing interfering factors: e.g., the impact of pathogen reduction technologies (PRT) on nAb has experimentally been shown to be apparently minimal (42, 43), but their impact on Fc-dependent functions (such as ADCC) is still to be investigated and could be relevant for some PRTs (44) (used e.g. in TSUNAMI (45), NCT04356534 (46), and ConPlas-19 (47). In this regard, we note that an early study reported that methylene blue reduced the protective function of antibodies to pneumococcus by interfering with glycosylated domains, raising concerns that it could affect Fc function (44). Of relevance, the various pathogen-reduced plasma went through clinical evaluation to assess their hemostatic activity linked to coagulation factors, or, at best, Fc binding to receptors (48), not their immunological activity: furthermore, none of the photochemical processes used for CCP is used in the field of plasma fractionation, and therefore we cannot make inferences from pharmaceutical-grade immunoglobulins.

The therapeutic dose of nAb is a product of its concentration in the infused CP multiplied by the overall infused CP volume, adjusted to the recipient body weight to take account of dilution into the blood volume and tissues. RCTs have varied in the provision of volume per unit (200-300 ml), and most importantly in cumulative volume per patient (1-4 units) and in extent of exposure to diverse antibodies from various CCP donors, and no published trials have adjusted levels of nAbs by recipient body weight (or, when attempts have been performed, they referred to the historical 10-15 ml/kg dose derived frm the treatment of hemorrhagic coagulopathies (49)). A failure of CCP to improve outcomes when 200-ml of 1:160 nAb-titer CCP is provided to a patient who weighs 120 kg represents quite a

different scenario from failure of a 600-ml transfusion of 1:640 nAb-titer CCP to produce improvement

in a 60-kg patient. But these central issues in dosage have not been considered in the RCTs

284 published so far.

Finally, antibodies other than nAbs can play a prominent role in viral clearance. Bahnan et al have

shown that CCP and anti-Spike mAbs induce phagocytosis but with diminishing returns when the

antibody concentrations become high: activation and inhibition of phagocytosis are independent of

neutralization potential and humanized ACE2 mice are protected from intranasal challenge by non-

neutralizing antibodies (50).

Relevance of CCP to the viral variant

292 Albeit not formally demonstrated, CCP manufactured by pooling ABO-matched units from many

different donors (e.g., in PlasmAr (12)) theoretically have greater polyclonality of nAbs than repeated

CCP doses from a single-donor (e.g. CAPSID (51)) and should grant higher efficacy against viral

variants. Nevertheless, pooling typically occurs among donors attending the same blood bank,

making donor exposure to different viral variants unlikely.

An analysis of potential variables associated with CCP efficacy associated near-sourcing with reduced mortality, with the efficacy of CCP in reducing mortality falling sharply when the CCP source was more than 150 miles from where it was used (52). This finding suggests that SARS-CoV-2 variants atsome geographic locations create antibody responses in CCP that are not effective against other variants at different locations (53, 54). Even though CCP is often standardized for nAb titer to the Spike protein, the VNT could use a nonrelevant viral strain, or miss major functional differences for the antibody response (41). This finding has implication for RCTs that use nationally sourced (centralized) CCP, since the attempt to standardize the therapeutic units centrally could inadvertently reduce CCP efficacy if hospitals use CCP obtained from distant loci. For example, in the C3PO RCT, which was conducted in 21 USA states, 95% of the donor CCP was collected in either Chicago or Denver: since only 4 of the 48 centers were in Illinois or Colorado, most CCP usage had to be from remote sources (27). The same concern applies to large multinational RCTs such as REMAP-CAP

(34). By contrast, the NCT04359810 RCT in New York and Brazil, which found a beneficial effect of

CCP on mortality, used CCP locally sourced in New York, whose efficacy against P.1 was tested to

ensure efficacy at the other recruiting center in Brazil (11).

Although also not formally demonstrated during clinical trials, it is also reasonable to assume that CCP collected during early pandemic waves could be less effective against currently circulating variants of concern (55). RCTs whose recruitment was protracted across multiple pandemic waves (e.g., ConPlas-19 (47) and TSUNAMI (45)) and which relied on CCP collected and banked months earlier could have inadvertently used CCP with reduced activity against the SARS-CoV-2 strains circulating the community when the therapy was administered. No CCP study to date has ever annotated or retrospectively performed SARS-CoV-2 sequencing on CCP donors nor on patients to identify the underlying variant: matching of the convalescent donor and the recipient for viral variant

has neber been formally achieved. Hence, both geography and time of collection of the CCP are important variables when considering the efficacy of the treatment.

The intended outcomes

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

Most trials (CONTAIN (26) and PassItOn being exceptions) have used composite endpoints or specialty scores (e.g., SOFA) rather than progression in the simple WHO ordinal scale or mortality, and many were stopped because of apparent futility at a time when they may have been underpowered to detect significant benefit. As represented in Figure 2, several studies have reported overall negative results (panel A) despite the presence of positive signals of efficacy just barely missing statistical significance (panels B and C). The significance level (i.e., p=0.05) is largely a socially constructed convention for rejecting the null hypotheses, but it has often been misinterpreted as a measure of reality by many individuals not familiar with the nuances of statistics. For example, some CCP studies have concluded that a difference that did not achieve a p value < 0.05 was an absence of difference, even when mortality in the CCP arm was ~20-40% lower than in controls (11, 47, 51, 56). This reasoning has played a central role in the polarized views of CCP efficacy and has impeded subsequent studies from drilling down on positive effects that were observed. The dogged pursuit of statistical significance, viewed as a measure of reality instead of the actual reality demonstrated by the data, during a public health emergency dealt a serious blow to studies of CCP and created significant confusion for clinicians. It is also important to understand that RCTs are powered to be less tolerant of Type I error than Type II error, which are conventionally set at .05 and .20, meaning that a Type II error is expected four times as often as a Type 1 error. This statistical convention can contribute to the absence of significance in studies that were set up early in the pandemic when there was little information on expected effects for the various patient populations studied, when power estimates were only guesses, and the enrolled patients were so heterogenous that only subgroups were likely to have responded to CCP treatment. Many studies were originally designed to enroll inpatients at any disease stage, and it should be no surprise that subgroup analyses on the groups that were later demonstrated to be more likely to benefit from CCP (e.g., early treated, seronegative patients, those receiving high nAb titre) were underpowered to reach statistical significance, as shown by orange color predominance in panel C of Figure 2. Nevertheless, favorable trends are a shared feature across such trials (5, 11, 12, 27, 47, 49, 51, 56, 57).

Rrigid adherence to primary outcomes that were often fixed in the early days of the pandemic when information about disease stage and quality of CCP associated with efficacy were not understood has contributed further to the confusion. When these outcomes were not met, trials were considered failures even though there were often signals of efficacy in the data that were not considered as valuable since these had not been pre-specified, even when they made biological sense. For example, in the New York-Brazil RCT cited above, CCP did not lower the primary end-point of clinical status on an ordinal scale, but the statistically significant halving of mortality was acknowledged in the abstract. Would it have made sense to ignore the strong effect of CCP on mortality in this trial just because mortality was not selected as a primary outcome? RCTs of mAbs (58) and dexamethasone

(59) were designed to achieve a tiny 6% and 4% reduction in mortality, respectively, while several

CCP RCTs failed because their initial assumption in the magnitude of reduced mortality was more

optimistic (e.g. TSUNAMI (45)).

Another misunderstood endpoint is viral clearance, defined as the conversion of nasopharyngeal

swabs (NPS) from positive to negative for PCR evidence of SARS-CoV-2 in CCP-treated patients.

While there was early and robust evidence for this effect from CCP (4, 10), sampling NPS too late

after CCP treatment, when the endogenous immune response had also mounted in the control arm,

could miss differences.

Analyzing conflicting outcomes in individual RCTs.

We use the word 'failures' with care and considerable nuance, since negative trials can be very important in teaching us about populations that do not benefit from CCP or variables that affect its efficacy. Keeping the factors discussed above in mind, we have analyzed individual RCTs in detail. At the very beginning, many historically or internally controlled observational studies showed clinical benefit from CCP (4-6) and this led the FDA to issue an EAP in March 2020 that was converted into an emergency use authorization (EUA) in August 23, 2020. The largest observational study is the US open-label EAP (NCT04338360) led by Joyner *et al*, which enrolled 105,717 hospitalized patients with severe or life-threatening COVID-19 from April 3 to August 23, 2020 (60). In an analysis of the effect of antibody in CCP performed independently of the results cited above (8) and using a nAb titer in an overlapping but non-identical group of EAP patients, the FDA showed that the 7-day mortality in non-intubated patients who were younger than 80 years of age and were treated within 72 hours after diagnosis was 6.3% in those receiving high-titer CCP and 11.3% in those receiving low-titer CCP (https://www.fda.gov/media/142386/download).

In a later analysis of a larger (N = 35,322) subset of EAP patients, (including 52.3% in the intensive care unit (ICU) and 27.5% receiving mechanical ventilation), the 7-day mortality rate was 8.7% in patients transfused within 3 days of diagnosis but 11.9% in patients transfused ≥4 days after diagnosis; similar findings were observed in 30-day mortality (21.6% vs. 26.7%) (61). In an EAP study from Argentina, mortality after CCP was 18.1% among 3,113 patients treated within 3 days since hospitalization, 30.4% among 1380 patients transfused between days 3-7, and 38.9% among 226 patients transfused after day 7 (62). The major criticism of these results is that controls were neither randomized nor PSM: hence a difference in the treatment outcome between treated and untreated groups may be caused by a factor that predicts treatment rather than by the treatment itself. However, importantly, nAb titer analysis was retrospectively done, both patients and physicians were unaware of the nAb content in the CCP units used, the results are what would have been expected from the experience with antibody therapy, and multivariate models were used to adjust for potential confounders (1). Additionally, given the outline of an optimal use case with this data and the earlier underpowered RCT by Li *et al* (5), it is unfortunate that due to (a) lack of awareness and (b) logistical burden associated with protocol adjustments, involving repowering and new patients' recruitment

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

criteria, later treatment RCTs either continued or initiated without modifications to include newly available evidence. The highest level of scientific evidence in primary clinical research stems from prospective PSM and RCTs. PSM studies (Table 3) balance treatment and control groups on a large number of covariates without losing a large number of observations. Unfortunately, no PSM study to date has investigated nAb titers by VNT or outpatients. Nevertheless, in 2 retrospective PSM studies from 2 different hospitals in New York, trends for improved outcomes in non-intubated and those treated within 7 days since hospitalization (HR 0.33) were observed (63, 64). These findings were later confirmed in a prospective PSM study from Houston (65, 66). Of interest, a retrospective PSM study from Providence did not show any benefit, but patients were treated at a median of 7 days after onset of symptoms (67). Another PSM study from Yale associated CCP with a 35% reduction in mortality (68). That study is notable in that it included patients on mechanical ventilation who would not normally be expected to benefit from CCP and the percentage of individuals receiving corticosteroids was very low since the study was conducted in the early days of the pandemic in the USA. Another PSM from the Washington DC area found a reduction in mortality with CCP use at both days 14 and 28, which reached statistical significance at the earlier date (69). Finally, a very large study from 176 community hospitals affiliated with HCA Healthcare confirmed substantial mortality reduction in hospitalized patients receiving CCP within 3 days from admission (70). Since PSM only accounts for observed (and observable) covariates, and not latent characteristics, RCT remains the gold standard for highest-level evidence (Table 2). In the PlasmAr RCT, the small number of early arrivals (less than 72 hours) showed superior primary and secondary outcomes in the CCP arm (n= 28) compared to the placebo arm (n=11), but the minimal contribution of this group to the overall cohort (228 CCP and 105 placebo) made the advantage disappear in the final outcomes at day 30 (12). In another Argentinean RCT on 160 outpatients older than 65 years of age with mild COVID-19 who were treated with CCP within 72 hours, progression to severe COVID-19 halved at day 30 (71). Similar findings were reported in outpatients without risk factors in CSSC-004 (29). An RCT from India reported that patients younger than 67 treated at a median of 4 days after hospital admission manifested superior mitigation of hypoxia and survival in the CCP arm (72). Another RCT in Spain enrolling patients at less than 7 days of hospitalization showed four deaths in the control arm, none in the CCP arm (47). Similarly, the ConCOVID RCT showed reduced mortality in the CCP arm (35).An additional complexity in recruitment to CCP trials is time to treatment. Clinical trials involve administrative requirements and consent procedures, and recruitment to a RCT further requires randomization, which may produce delays in treatment. CCP therapy requires cross-matching of blood types, ordering the CCP, which may or may not be available on site, and setting up the transfusion. This inherent delay from randomization to infusion means that RCTs may build in a disadvantage for the CCP study arm in the few RCTs using control treatments (e.g. saline or fresh frozen plasma (FFP)), where controls may have received treatment earlier in the disease course : for example, FFP was used in NCT04346446 (57), NCT04359810 (11), NCT04344535 (56), COV-Early

- 436 (28), and CSSC-004 (29) RCTs. ABO-compatible CCP units may be not readily available at the local
- 437 blood bank and recruited patients may have to wait for a compatible unit of CCP. These almost
- 438 inevitable delays from randomization mean that CCP may be provided later in the illness than is ideal,
- and even if the trial intends to treat early, in practice it may not be possible unless the RCT is
- designed to deliver plasma immediately after randomization.
- 441 During a pandemic, moreover, delays in treatment are magnified. The accrual of severely ill patients
- 442 in emergency departments and the overwhelmed or even collapsed health care systems can create
- long delays from arrival in the emergency room to treatment. In the absence of quick (antigenic or
- 444 molecular) tests for SARS-CoV-2, the turnaround time for final confirmation of diagnosis with PCR,
- which must often be run in batches, can take several hours. All these factors are likely to impact the
- 446 efficacy of CCP treatment. To shorten such time, fully screened CCP collected from eligible donors
- 447 (73) could be safely administered within emergency departments shortly after admission and even
- before the patient reaches the ward.
- 449 Figure 2 graphically places the outcomes of RCTs and PSM studies on a Cartesian plot having
- 450 timeliness and nAbs dose as variables (if values are disclosed in the reports): this makes immediately
- clear that the few successes at reaching the primary endpoints have gathered into the lower right
- 452 corner (high nAb dose and early intervention), while the many conflicting outcomes have been
- scattered all around (panel A), reflecting lower antibody levels infused or late treatment, or both, with
- 454 the latter being the commoner problem. Nevertheless, when we focus on mortality irrespective of
- statistical significance (panel B) or focusing on statistical significance (panel C), many more RCTs
- 456 showed clear benefits.

468

469

470

- We will focus here on "failures" as identified by title, abstract and/or press recognition. Narratively, we
- 458 could group so-called "failures", with failure implying inability to demonstrate a favorable outcome to
- 459 CCP use, into 4 categories, according to the main reasons:
- 1. Trials that transfused insufficient therapeutic doses of CCP due to either low total IgG levels or low nAb levels (e.g., PLACID (10))
- 2. Trials that transfused appropriate doses of CCP but too late, but which nevertheless reported signals of efficacy (e.g., RECOVERY (49), CAPSID (51), NCT04359810 (11) and TSUNAMI (45))
- 3. Trials that were stopped too early to observe benefit or with inherent design flaws, and/or were underpowered such that likelihood of success was reduced (e.g., C3PO (27))
 - Trials in which CCP was used to treat a condition not amenable to antibody intervention, such as hypoxia that is caused by pulmonary inflammation (e.g., COP20 (74) or REMAP-CAP (34))

The inadequacy of meta-analyses.

- With all the heterogeneity in key drivers discussed in the former paragraphs, it becomes clear that
- 472 secondary research (ranging from umbrella reviews to meta-analyses to systematic reviews), whereby

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

each study is considered at the same level, invariably ends up with biased and divergent conclusions. This adds confusion to the already complex field of individual trial outcomes. Amazingly, as of December 21, 2021, PubMed has indexed 26 meta-analyses on CCP efficacy, more than the RCTs reported at the same date. Until the beginning of 2021, meta-analyses (variably including observational studies) were generally in favor of CCP (75), but began to be biased towards failure after publication of the large RECOVERY trial (49), which, by enrolling as many as 11,448 patients, diluted all the signals from positive RCTs. Clear examples of this phenomenon come from a widely cited metanalysis from Janiaud et al in JAMA (76) which included press release data from RECOVERY, and from the living systematic review by the Cochrane Group (77). The JAMA paper was surely unprecedented in the tradition of meta-analysis, not only because it included a study based only on a news release (which proved to differ in some important respects from the published paper), but because it allowed these data from a news release to dominate the entire analysis. At November 2021, in a follow-up metanalysis from the same group on 16,477 patients from 33 trials, RECOVERY still weighted 69.8% (78). Several groups attempted to dissect the RECOVERY trial and others by running subgroup analyses in their systematic reviews (79-81), but these reviews were unable to restore confidence in CCP efficacy in the clinical community that had been lost because of the publication of the overall negative findings of RECOVERY and PlasmAr (82). Merely following such metanalyses, on December 7, 2021 the WHO revised its living guidelines on drugs for COVID19, discouraging usage of CCP (83): such contraindication received large criticisms from both the SUPPORT-E (84) and CCPP19 consortia. Actually, metanalyses embedding more recent studies and performing subgroup analysis were more positive on the beneficial effects of CCP. A metanalysis of 22,591 patients (enrolled in 10 RCTs and 15 observational studies) showed that early CCP significantly reduced mortality (RR 0.72, p<0.00001), but only in patients who were not suffering severe or critical disease (85). Another metanalysis of 18 peer-review clinical trials, 3 preprints, and 26 observational studies actually found that CCP use was associated with reduced risk of all-cause mortality in severe or critical COVID-19 patients (86). A recent umbrella review of 29 metanalyses and systematic reviews found evidences for improvement in the CCP arms for some outcomes (overall mortality, viral clearance at day 3,) but not for others (clinical improvement, length of hospital stay (87). Rather than pooling published RCTs, the Continuous Monitoring of Pooled International Trials of Convalescent Plasma for COVID-19 Hospitalized Patients (COMPILE) study pooled individual patient data from ongoing RCTs at two-week intervals. Unfortunately, with the single exception of CONTAIN (26), participating RCTs largely shared usage in advanced disease stages (DAWN-plasma (33), PLACID (10), ConCOVID (35), ConPlas-19 (47), NCT04421404, PennCCP2 (88), and the Brasília Covid-19 Convalescent Plasma (BCCP)) (89). Current clinical utility of CCP While CCP contains a plethora of biologically active molecules (90), we now have very strong evidence that appropriately vetted CCP from eligible convalescent donors is safe for patients (91, 92), with no evidence of increased risks of transfusion-transmitted acute lung injury, antibody-mediated enhancement concerns feared in the early days of the pandemic (93) nor is

513

514

515

516

517

518

519

520

521

522

523

524

525 526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

there evidence that CCP induces accelerated SARS-CoV-2 evolution (11). Polyclonal antibodies such as CCP are likely to offer better protection against onset of variants than monoclonal antibodies (94-96): importantly, Pommeret et al showed that CCP can rescue immune escape variants emerged during treatments with bamlanivimab/etesevimab cocktail (97). Outcomes in immunocompromised patients treated with CCP have been successful in the long-term, with minimal evidence for immune escape (98). We have also learned that CCP is less likely to benefit patients requiring oxygen (i.e., from level 4 and up on the 11-point WHO ordinal scale), and hence, ideally, the focus should be on outpatients and in identifying that subset of patients who seek hospital care and are still sufficiently early in the course of disease such that they can benefit from CCP. This finding parallels the finding with hyperimmune serum and anti-Spike monoclonal antibodies, which at first failed in hospitalized patients (99, 100), but later succeeded for ambulatory patients with mild to moderate COVID-19 (101) and were approved for emergency use. However, at this moment clinical use in the US is restricted by the FDA to inpatients. CCP usage per admission peaked after issuance of the EUA, with more than 40% of inpatients estimated to have received CCP between late September and early November 2020. Oladunjoye et al showed that mortality in the second wave in USA, when utilization of corticosteroids, remdesivir and convalescent plasma was higher, was lower than the first wave (102). However, following reports of RCTs that failed to show clear benefit from CCP, usage per admissions declined steadily to a nadir of less than 10% in March 2021. A strong inverse correlation (Pearson correlation coefficient of -0.5176 with P = 0.00242) was found between CCP usage and deaths occurring 2 weeks after admission, and this finding was robust to examination of deaths taking place 1, 2 or 3 weeks after admission. Changes in the number of hospital admissions, prevalence of variants, and age of patients could not explain these findings. The authors estimated that the retreat from CCP usage, a phenomenon they termed "plasma hesitancy", might have resulted in 29,000 to 36,000 excess deaths in the period from mid-November 2020 to February 2021 (103). The same analysis estimated that USA had avoided 96,000 excess deaths from August 2020 to March 2021 by its liberal deployment of CCP. Several lines of evidence, ranging from the EAP to clinical trials employing RCT or PSM controls are now indicating how CCP should be used in immunocompetent patients (104). The evidence supports the initiation of CCP treatment as early as 44-72 hours within onset of symptoms (which largely pertains to outpatients) and using CCP with a nAb titer > 1:160. Benefit within 1 week from onset of symptoms (including in hospitalized patients) is less well understood, although a benefit from higher therapeutic doses cannot be ruled out at this stage. Clinical benefit seems absent when administered after 1 week from onset of symptoms or in patients requiring ventilation, or in those who receive CCP with a low nAb titer. Nevertheless, chronically immunosuppressed patients benefit from CCP even at later stages (98, 105, 106): the best evidence for this scenario comes from a prospective PSM showing a halving of mortality in ICU-admitted oncohematological COVID-19 patients who received CCP (107). We note that while there have been concerns that use in immuncompromised can promote the emergence of antibody-resistant variants, such variants have emerged from massive replication in susceptible populations and not from treated patients, who in any case are isolated in

hospitals where mitigation efforts to reduce transmission are employed, and are thus very unlikely to transmit their viruses further (108). Such simple concepts have been poorly communicated to the general public and the clinical community, who should be better informed on the settings where CCP has shown efficacy and the ones where it has not.

Recommendations

551

552

553

554

555

556 557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

Stopping trials for futility is an occurrence that deserves special attention, because it represents wasted resources during a pandemic. Eight RCTs so far have been halted for futility, namely RECOVERY (49), REMAP-CAP (34), CONCOR-1 (109), C3PO (27), NCT04361253 (ESCAPE), CoV-Early (28), and COP20 (74), with the first one being to date the strongest evidence for futility (49), with its massive recruitment affecting the outcomes of systematic reviews (76). Instead of stopping trials for futility based on pre-set endpoints it makes more sense that DSMBs facing a high likelihood of lack of statistical significance provide advice on trial modifications that are likely to amplify the significance of signals of efficacy evident in these studies. This would seem a more responsible action than trial cessation given the paucity of therapeutic alternatives in the pandemic emergency.

More flexibility is needed when dealing with a new virus since estimates of efficacy and the required power can change tremendously as the data accumulates. For example, some RCTs were designed to evaluate efficacy at day 15 but subsequently we learned that this time was too early since mortality often occurs later (26). Indeed, a Bayesian re-analysis of RECOVERY data with a wide variety of priors (vague, optimistic, skeptical and pessimistic) calculated the posterior probability for both any benefit or a modest benefit (number needed to treat of 100). Across all patients, when analyzed with a vague prior, the likelihood of any benefit or a modest benefit was estimated to be 64% and 18% respectively. In contrast, in the seronegative subgroup, the likelihood of any benefit or a modest benefit was estimated to be 90% and 74% (79). This finding of benefit accruing to specific subgroups, who were not determined post-hoc but because they were likely to benefit based on understanding of principles of CP treatment is found in nearly every trial whose overall finding is negative. This effect is more reflective of a problem with RCT design and execution than a limitation on the efficacy of CCP. Although we agree that subgroup analysis carries the risk of 'cherry picking' data, such analyses are often important for hypothesis generation and critically important during the emergency of a pandemic where neither viral pathogenesis nor therapeutic variables are well understood. When sub-group analyses are based on firm biological principles, such as focusing on those treated early in disease or lacking their own serological response, the exercise may be warranted. To emphasize this point, Christopher Columbus missed the pre-specified primary endpoint of his mission - reaching India - but no one considers his discovery of the New World to be a failure! Turning to the clinical arena, most trials of anticoagulants in myocardial infarction found reductions in mortality of about 20-25%, which was generally not significant in these underpowered trials that declared the findings to be null, even though such a mortality reduction would clearly be of value (110). Given that conventional peer-review slows down during a pandemic, pre-publishing RCT results by the preprint mechanism should be encouraged to accelerate sharing of potentially lifesaving therapeutic approaches and to provide pre-publication review that could improve the quality of the final published study.

The future of CCP

CCP remains a relatively inexpensive therapy that is available throughout the world even in resource poor areas that cannot afford expensive antiviral drugs or monoclonal antibody therapies. Much has been learned about the variables that affect CCP efficacy even though, as recounted here, the clinical efficacy data is mixed. Table 4 lists the RCTs whose outcomes have still to be reported after completion or which are still recruiting patients. Unfortunately, little new can be expected given that most of these RCTs were designed to enroll patients having symptoms for more than 7 days. Given the heterogeneity of the product and the complex variables that contribute to efficacy it is remarkable that many studies have reported reductions in mortality. This suggests a likely therapeutic effect that allow signals of efficacy to break through all the noise imposed by variability in the product and its clinical use. The positive evidence for CCP efficacy cannot be dismissed while in many cases negative results can be explained. In the absence of good therapeutic options for COVID-19, CCP is likely to find a niche in the early treatment of disease. Instead of looking for unlikely superiority outcomes, noninferiority RCTs comparing mAbs versus CCP in early arrivals should be initiated. Such an RCT is very unlikely to be sponsored by vendor companies, so public institutions should be sensitized to funding it.

There is evidence that vaccinated convalescents may have even higher nAb titers than unvaccinated convalescents (111), and that nAbs are more effective against VOCs than those from unvaccinated convalescents (112, 113), offering the promise of expanded success in using CCP. The higher frequency of high-titer donors would make donor screening more cost-effective. Being collected from individuals far from hospital discharge, and eventually periodic blood donors, it is unlikely that those units would benefit from further infectious risk minimization with PRTs, reducing the final cost and avoiding the previously discussed potential confounder of the inactivation method interfering with antibody function. Hence future CCP trials that will start after mass vaccination campaigns should preferentially rely over CCP from vaccinated donors. That said, inclusion of vaccinated individuals (e.g. CSSC-004 (29)) in future RCTs is also a potentially confounder. Indeed those individuals are at lower risk, thus increasing the outpatients NNTT to prevent a single disease progression, and also complicating the identification of seronegative individuals who are more likely to benefit from nAbs.

Low-to-middle income countries (LMIC) are likely to benefit the most from CCP, given they cannot afford massive deployment of mAb or small-chemical antivirals. Research is ongoing to spare some of cold chain requirements for CCP relying over freeze-dried plasma (FDP), which has been shown to preserve nAb functions for months at ambient temperature (114).

On November 8, 2021, the sudden emergence of the SARS-CoV-2 Omicron VOC with its 32 Spike mutations was an alarming development because it threatened to prolong the pandemic and undermine the immunity gains made with vaccination campaigns. Computer modeling and *in vitro* VNT soon confirmed full escape from clinically used mAb cocktails (including

bamlanivimab+etesevimab, REGN-CoV-2 and AZD7442) (115, 116). While it was already known that mAb cocktails were less likely to experience immune escape than single mAbs, most of the scientific community underestimated the risk from major shifts in the 3D Spike structure. Combined with the lengthy manufacturing and approval process for mAb therapies, such sudden shifts largely hinder primarily mAb-based therapies, since polyclonal approaches such as CCP are less vulnerable to loosing activity. While even CCP is vulnerable to losing some efficacy with VOC that manifest partial immune escape, the probability and extend of reduction are far lower (117).

Given the experience accumulated with COVID-19, it is almost certain that CCP will again be considered to deal with the surges yet to come in the current epidemic as well as for the next epidemic. One of the good legacies of the COVID-19 pandemic is that an enormous international research effort had produced a large body of data that teaches how to best use CCP. The lessons learned reinforce the experience of the past, namely that best results are obtained with high titer CCP administered early in the course of disease. We are hopeful that lessons learned in this pandemic are heeded such that use and trials focus on the very early use with high-titer CCP.

We declare we have no conflict of interest to disclose.

Figure 1

Simplified graphical representation of CCP RCTs reported ot date, plotted according to earliness of intervention and disease severity (stratified according to WHO 11-category ordinal scale (25): 0: uninfected; no viral RNA detected; 1: asymptomatic; viral RNA detected; 2: symptomatic; independent; 3: symptomatic; assistance needed; 4: hospitalized, no oxygen therapy; 5: hospitalized; oxygen by mask or nasal prongs; 6: hospitalized; oxygen by NIV or high flow; 7: intubation and mechanical ventilation, pO2/FiO2 ≥ 150 or SpO2/FiO2 ≥ 200; 8: mechanical ventilation, pO2/FiO2 < 150 (SpO2/FiO2 < 200) or vasopressors; 9: mechanical ventilation pO2/FiO2 < 150 and vasopressors, dialysis or ECMO). Green text indicates trials which met the primary endpoint with statistical significance; orange text indicates trials which failed to meet the primary endpoint but showed statistically nonsignificant trends in favor of CCP; red text indicates trials which failed to show and benefit from CCP in the primary endpoint.






Figure 2

Simplified graphical representation of CCP RCTs reported to date, plotted according to earliness of intervention and nAb titers in CCP. In **panel A**, green text indicates trials which met the primary endpoint with statistical significance; orange text indicates trials which failed to meet the primary endpoint but showed statistically nonsignificant trends in favor of CCP; red text indicates trials which failed to show and benefit from CCP in the primary endpoint. In **panel B**, green text indicates trials which showed overall mortality benefit from CCP; orange text indicates trials which showed mortality benefit from CCP in the subgroup of early arrivals or higher nAb titers; red text indicates trials which failed to show any mortality benefit from CCP. In **panel C**, green text indicates trials which showed statistically significant mortality benefit from CCP (overall or in the subgroup of early arrivals or higher nAb titers); orange text indicates trials which showed statistical trends towards mortality benefit from CCP (overall or in the subgroup of early arrivals); red text indicates trials which failed to show any mortality benefit trend from CCP in any subgroup. Underlined text indicates large trials which were not RCT and for which nAb levels was inferred from high-throughput serology, but are nevertheless reported as reference studies. Numbers in parenthesis indicate cumulative number of patients enrolled.








Table 1

Details of viral neutralization tests (VNT) employed in CCP RCTs. Information was retrieved from original article (including Supplementary Appendix). Whenever not reported, the corresponding author was contacted (marked with *). If the details could not be retrieved the field is labelled "n.a." (not available). IC: inhibitory concentration. NT: neutralization titer. PFU: plaque-forming unit; PRNT: plaque reduction neutralization test.

	RCT (acronym/first	cell line	cells seeded	virus	virus	multiplicity	le ng thof	assay	threshold	protocol
	author)		per well	lineage	per	of infection	incubation	read-out		reference
					well	(MOI)				
authentic live SARS- CoV-2	NeuCoV-NET NCT04393727 (TSUNAMI)	Vero E6	12,000	SARS-CoV- 2/Human/IT A/PAVIA107 34/2020 (D614G)	100 TCID ₅₀	0.01	until the cytopathic effect (CPE) became evi dent.	CPE	last serum dilution that inhibited SARS-CoV-2 CPE by 90%.	(118)
(B h h F P (N	NCT04433910 (CAPSID)	Vero E6	n.a.	n.a.	100 PFU	n.a.	3 days	СРЕ	PRNT ₅₀	(119)
	Broad Institute on a high throughput platform (BROAD PRNT). Part of NCT04355767 (C3PO)	Vero E6-TMPRSS2	10,000	SARS-CoV-2 live virus (D614)	n.a.	n.a.	48 hours	N-protein ELISA	samples whose curves lay above 0.5 for all the data points were considered non-neutralizing, with ID ₅₀ =20, while samples whose curves fell below 0.5 were considered highly neutralizing and assigned an ID ₅₀ =10,240.	(120)
	NCT04359810 (O'Donnell)	Vero E6	10,000	2019- nCoV/USA- WA1-2020	100 TCID ₅₀	0.01	48 hours	Triplex CII-SARS- CoV-2 rRT-PCR Test, EUA2005 10).	the highest CCP dilution that prevented virus growth (cycle threshold [Ct] was rated as neutralization titer.	(11)

NCT04348656	Vero-E6	n.a.	Can a da/ON	50	n.a.	72 hours	СРЕ	PRNT ₅₀	(109)
(CON COR-1)			_ON-VIDO-	PFU					
			01-2/2020,						
			EPI_ISL_425						
			17						
NCT04342182	Vero-E6	n.a.	German	400	n.a.	8 hours	CTL	reciprocal of the highest dilution	(35)
(ConCOVID)			isolate	PFU			ImmunoS	resulting in a reduction >50% of	
			(GISAID ID				pot	infected cells (PRNT ₅₀)	
			EPI_ISL				mage		
			406862)				Analyzer		
NCT04429854 (DAWN-	Vero E6	n.a.	BetaCov/Bel	100	n.a.	5 days	CPE	PRNT ₅₀	(121)
plasma)			gium/Sart-	TCID ₅₀					
			Tilman/202						
			0/1						
		18,000	2019-nCoV-	3	n.a.				(122)
			taly- NM 1	TCID ₅₀					
		n.a.	Belgium/GH	400	n.a.	4 days			(123)
			B-03021/20	PFU					
			20						
		20,000	Belgium/S1	100	n.a.	2 days	anti-N	NT ₅₀	(124, 125)
			871/2020	TCID ₅₀			staining		
Australian part of	Vero E6	20,000	hCoV/Austr	200	0.01	3 days	CPE	n.a.	(126)
NCT02735707			alia/VIC01/	TCID ₅₀					
(REMAP-CAP)			202011 and						
			hCoV/Austr						
			alia/VIC208						
			9/2020						
Canadian part of	Vero E6	n.a.	Can a da/ON	50	n.a.	3 days	СРЕ	n.a.	(127)
NCT02735707			_ON-VIDO-	PFU					
(REMAP-CAP)			01-2/2020						

	RBR-7f4mt9f	Vero (CCL-81)	50,000	n.a.	n.a.	n.a.	3 days	СРЕ	n.a.	(128)
Spike	Vitalant Research	ACE2 and TMPRSS2	n.a.	VSV	n.a.	n.a.	18-24 hours	chemilum	NT were calculated as a	(120)
p seu do type	Institute (VRI)	expressing HEK293T		pseudotype				inescence	percentage of no-serum control	
d viruses	Pseudovirus	cells		d with				reader	and the NT ₅₀ was estimated from	
	N eutralization			Wuhan-Hu-					the dilution curve	
				1 Spike (
	Part of N CT04355767			D614G						
	(C3PO)			mutation						
				and without						
				21 C-						
				terminal aa)						
	NCT04383535	Vero- CCL81	20,000	VSV	n.a.	n.a.	18-22 hours	luminom	IC ₅₀ is calculated as the midway	(129)
	(PlasmAr)			pseudotype				eter	point between the upper and	
				d with Spike					lower plateaus of the curve.	
				(CoV2pp)					abs C ₈₀ appeared to be a more	
				and					stringent measure of nAb activity,	
				carrying					as some sera that have	
				Renilla					respectable MN abs C ₅₀ titers	
				luciferase					never achieve an absIC _{80:} this is	
				gene in					due in part to the difference in	
				place of its					the dynamic ranges bet ween a	
				G					luciferase-based assay (≥3 logs	
				g ycoprot ei					RLUs) and a MN assay (~1.5-log	
				n (VSV∆G-					optical density [OD] values	
				rLuc).					corresponding to the amount of	
									viral protein detected).	
	CTRI/2020/04/024775	Vero CCL-81	10,000	SARS-CoV-2	n.a.	n.a.	36 hours	luminom	n.a.	(130)
	(PLACID)	293 T/ACE2 cells		strain				eter		
				NIV2020770						
	NCT04345523	Vero E6	5,000	lentivirus	titrate	n.a.	48 hours	luminom	ID ₅₀ expressed as the highest	(23)

ConPlay 19)									·	
and luciferase att v ty compared to contro without serum. Sigm of curves were generated and ID ₁₀ neutral zation titlers (NID ₂₀) were callouted by non-linear regress on every generated and ID ₁₀ neutral zation titlers (NID ₂₀) were callouted by non-linear regress on every generated and ID ₁₀ neutral zation titlers (NID ₂₀) were callouted by non-linear regress on every generated and ID ₁₀ neutral zation titlers (NID ₂₀) were callouted by non-linear regress on examples with a neutral zing activity of at least 50% at a 1:160 dilution of the every generated and solve at a 1:160 dilution of the every generated and ID ₁₀ neutral zing activity of at least 50% at a 1:160 dilution of the every generated and solve at a 1:160 dilution of the every generated and so	(ConPlas-19)			pseudotype	d at 10			eter	dilution of plasma (reciprocal	
lucferase lucferase lucferase lucferase lucferase addivity compared to control without serum. Sign old curves were generated and ID ₂₀ , neutralization inters (NT _{Ed} were calculated by non-linear regression NCTO4375098 (Ewira- Balcels) N. a. N. a				d with Spike	ng p24				dilution), which resulted in a	
NCT04375098 (Bivira- Baicels) HEK293T/hACE2 10,000* HIV-1-5.019 pseudotype d with Spike (Genebank: QH38824, 11 and luciferase NCT04346355 N.a. R.a. PRNT and pseudovrus NCT0450440 (COP20) NCT04600440 (COP20) Vero E6 10,000 PFU NCT04600440 (COP20) Vero E6 10,000 PFU NCT04600440 (COP20) Vero E6 NCT04600440 (COP20) Vero E6 NCT04600440 (COP20) Vero E6 NCT04600440 (COP20)				and	Gag				50% reduction of luciferase	
were generated and D ₅₀ neutralization titers (NT ₅₀) were calculated by non-linear regression NCT04375098 (Evirable REK293T/hACE2				luciferase					activity compared to control	
NCT04375098 (Elvira-Balcels) NCT04375098 (Elvira-Balcels) HEK293T/hACE2 10,000* HIV-1-SA19 pseudotype d wth Spike (Genebank: OHU36824. 1) and lucferase NCT04344535 n.a. n.a. n.a. n.a. NCT04344535 n.a. NCT04500440 (COP20) Vero E6 10,000 PFU NCT04600440 (COP20) Vero E6 10,000 PFU NCT04600440 (COP20) NCT									without serum. Sigmoid curves	
NCTO4375098 (Evira-Baicels) NCTO4375098 (Evi									were generated and ID ₅₀	
NCT04375098 (Evirable Legis) NCT04500440 (COP20) NCT04500440 (COP20) NCT04600440									neutralization titers (NT ₅₀) were	
NCT04375098 (Elvira-Balcells) Balcells) HEK293T/hACE2 10,000* HIV-1-SΔ19 n.a. n.a. 48 hours* Logendotype d with Spike (Genebank: QHU36824 1) and luciferase NCT04344535 N.a. N.a. PRNT and pseudovirus NCT04600440 (COP20) Vero E6 10,000 Pseudovirus 10,000 Pseudovirus NCT04600440 (COP20) Vero E6 10,000 Pseudovirus 200 N.a. 8 hours Indirect immunofi uorescen ce IC ₂₀ values were calculated using measured by TROPHOS Plate RUNNER HD° TROPHOS Plate RUNNER HD°									cal culated by non-linear	
Baicells) Baicells									regression	
d with Spike (Genebank: QHU36824. 1) and luciferase NCT04344535 n.a. n.a PRNT and pseudovirus NCT04600440 (COP20) Vero E6 10,000 pseudovirus NCT04600440 (COP20) Vero E6 10,000 pseudovirus 200 n.a. 8 hours indirect immunoficular quantified and normalized to virus incubated without plasma. Ce ICs values were calculated using normalized data and a non-linear fit with variable slope. 10 dilution were considered positive and used to perform titration curves and IDso NT calculations 10 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a	NCT04375098 (Elvira-	HEK293T/hACE2	10,000*	HIV-1-S∆19	n.a.	n.a.	48 hours*	luminom	samples with a neutralizing	(131)
Company Comp	Balcells)			pseu dotype				eter	activity of at least 50% at a 1:160	
NCTO4344535 n.a. n.a. PRNT and pseudovirus 200 n.a. 8 hours Indirect immunofi ucrescen Ce Household (COP20) Vero E6 10,000 pseudovirus PFU PFU immunofi ucrescen ce Hospital (Coparation of the company o				d with Spike					dilution were considered positive	
NCT04344535 (Bennett-Guerrero) NCT04600440 (COP20) Vero E6 10,000 pseudovirus 200 pseudovirus An.a. PFU n.a. N.a. N.a. N.a. N.a. N.a. N.a. N.a. In.a. Indirect immun of i uurescen virus incubated without plasma. Ice iCs ₀ values were calculated using measured by TROPHOS Plate RUNNER HD°				(Genebank:					and used to perform titration	
NCT04344535 (Bennett-Guerrero) NCT04600440 (COP20) Vero E6 10,000 pseudovirus PFU NCT04600440 (COP20) Vero E6 10,000 pseudovirus PFU NCT04600440 (COP20) PFU NCT04600440 (COP20) PFU NCT04600440 (COP20) NC				QHU36824.					curves and ID ₅₀ NT calculations	
NCT04344535 (Bennett-Guerrero) Vero E6 10,000 pseudovirus 200 n.a. PFU 8 hours Indirect immunofl uorescen ce iCso virus incubated without plasma. 1050 virus incubated without				1) and						
NCT04600440 (COP20) Vero E6 10,000 pseudovirus 200 n.a. 8 hours Indirect immunofi quantified and normalized to virus incubated without plasma. IC50 values were calculated using normalized data and a non-linear fit with variable slope. TROPHOS Plate RUNNER HD°				luciferase						
NCT04600440 (COP20) Vero E6 10,000 pseudovirus 200 n.a. 8 hours Indirect immunofl uorescen virus incubated without plasma. ce ICso values were calculated using normalized data and a non-linear fit with variable slope. TROPHOS Plate RUNNER HD®	NCT04344535	n.a.	n.a.	PRNT and	n.a.	n.a.	n.a.	n.a.	n.a.	(56)
PFU immunofl uorescen virus incubated without plasma. ce IC ₅₀ values were calculated using measured by fit with variable slope. TROPHOS Plate RUNNER HD®	(Benn ett-Guerrero)			pseudovirus						
PFU immunofl uorescen virus incubated without plasma. ce IC ₅₀ values were calculated using measured by fit with variable slope. TROPHOS Plate RUNNER HD®										
uorescen virus incubated without plasma. ce IC _{so} values were calculated using normalized data and a non-linear by fit with variable slope. TROPHOS Plate RUNNER HD®	NCT04600440 (COP20)	Vero E6	10,000	pseudovirus	200	n.a.	8 hours	Indirect		(74)
ce IC ₅₀ values were calculated using normalized data and a non-linear by fit with variable slope. TROPHOS Plate RUNNER HD®					PFU			immunofl	quantified and normalized to	
measured by fit with variable slope. TROPHOS Plate RUNNER HD®								uorescen	virus incubated without plasma.	
by fit with variable slope. TROPHOS Plate RUNNER HD®								ce		
TROPHOS Plate RUNNER HD®										
Plate RUNNER HD®									fit with variable slope.	
RUNNER HD®										
HD®										
NCTO4364737 Vero n.a. VSV n.a. n.a. 7 hours automate IC ₅₀ (132)								HD®		
	NCT04364737	Vero	n.a.	VSV	n.a.	n.a.	7 hours	automate	IC ₅₀	(132)

(CONTAIN)	pseudovirus	d
		enumerat
		ion of
		GFP-
		positive
		cells

Table 2

 Randomized controlled trials (RCT) of COVID-19 convalescent plasma (CCP) reported to date, listed according to date of (pre-)publication. nAb: neutralizing antibodies. BSC: best supportive care. FFP: fresh frozen (nonconvalescent) plasma. n.a.: not assessed (i.e. antivirus antibodies were assessed only using high-throughput serology). IQR: interquartile range. Moderately late usage is defined as 4-6 days since onset of symptoms, late usage as 7-10 days, very late usage as >10 days.

RCT	recruitme	contr	median	baseline	transfu	median	median	main outcomes	likely reason(s) for	signals of efficacy	ref
identifier	nt (out of	ol	days before	recipient	sed	nAb titer	pretransfu	reported in	failure		
(acronym/	expected)	arm	randomizati	8-point	CCP	in CCP	sion nAb	abstract or			
first	(randomiz	(in	on	WHO	volum	units	titer in	conclusions			
author)	ation	additi		score*	e (ml)		recipient				
	strategy)	on to		(24, 25)	(patho						
		BSC)			gen						
					inactiv						
					action)						
NCT04479	160 (out of	BSC +	39.6 hours	2	250	n.a.	n.a.	progression to	no failure	main outcome	(71)
163	210) (1:1)	norma	(from					severe COVID-19			
(Libster)		1	symptoms;					halved at day 30			
		saline	and > 65								
			yrs)								
BKH-CT-	49 (1:1)	BSC	< 3 (from	5	400	n.a.	n.a.	duration of infection	no failure	main outcome	(133
012			RCU					reduced by 4 days;)
			admission)					mortality 1/21 in			
								CCP arm vs 8/28			
CTRI/2020	80 (1:1)	BSC	4.2 (from	5	200+20	n.a.	n.a.	immediate	no failure	main outcome	(72)
/05/02520			hospital		0			mitigation of			
9 (Raj)			admission)					hypoxia, reduction			
								in hospital stay as			
								well as survival			
								benefit was			
								recorded in severe			

										COVID-19 patients			
										with ARDS aged			
										less than 67 years			
ChiCTR20	103 (out of	BSC	30 (1	rom	5-6	200-	≥ 1:40	n.a.		no significant	moderately late usage	reduced mortality at day 28	(5)
00029757	`	ВЗС	,		5-0	200-	(inferred	II.a.		difference in 28-day	moderatery rate usage	only in WHO score 5	(5)
	200) (1:1)		symptom	S)			•			•		•	
(Li)							from			mortality (15.7% vs		patients (HR 2.5); negative	
							correlation)			24.0%) or time from		conversion rate of viral PCR	
										randomization to		at 72 hours in 87.2% of the	
										day-28 discharge		CCP group vs 37.5% of the	
										(51.0% vs 36.0%)		control group (OR, 11.39)	
NCT04342	86 (out of	BSC	10 1	rom	5-6	300	1:320	1:160	in	no benefit at day 15	very late usage, high rate	mortality in CCP group 14%	(35)
182	426) (1:1)		symptom	s; 2			(PRNT ₅₀)	79%	of		of seropositives	(6 out of 43) vs. 26% in	
(ConCOVI			from					recipient	ts			control group (11 out of 43)	
D)			hospitali	zati				(11%				(OR = 0.47)	
			on					seroneg	ati				
								ve)					
CTRI/2020	464 (1:1)	BSC	6 (1	rom	4-5	200+20	1:40	1:90 (1	7%	no benefit at day 28	moderately late usage;	none	(10)
/04/02477			symptom	s)		0		seroneg	ati		high rate of seropositives;		
5								ve)			extremely low nAb titre in		
(PLACID)											CCP		
NCT04345	350 (1:1)	BSC	8 (1	rom	3 (25%)	250-	1:292	n.a.		no significant	underpowered for	primary endpoint significant	(47)
523			symptom	s)	4 (75%)	300				differences in	mortality; primary	at day +28. Trends for	
(ConPlas-						(methyl				primary endpoint	endpoint set at just 15	reduced overall mortality (p	
19)						ene				(proportion of	days	= 0.087) at day +28,	
						blue				patients in		expecially in aged > 75	
						46.3%,				categories 5, 6 or 7		years. Primary and	
						riboflavi				(death) at 14 days		secondary endpoints	
						n 24%,						improved in methyelen	
						psorale						blue-treated CCP subgroup	
						n						compared to controls	
						19.6%,						(personal communication)	
						unknow							

					n 10.0%)						
NCT04375	58 (1:1)	late	6 (from	3-4	200+20	≥ 1:160	59% <	no benefit at day 30	underpowered,	none	(134
098		CCP	symptoms)		0		1:160	in death,	moderately late usage)
(Elvira-							(16% of	mechanical			
Balcells)							patients	ventilation or			
							enrolled	prolonged			
							before day	hospitalization			
							5 were	compared to CCP			
							≥1:160 vs	administration only			
							60% of	in case of clinical			
							those	worsening or > 7			
							enrolled	days after			
							after day 6	enrolment			
NCT04383	333 (2:1)	BSC +	8 (from	5	500	1:300 IC ₈₀	n.a.	no benefit at day 30	moderately late usage	early arrivals (less than 72	(12)
535		norma	symptoms)		(from a			(16.2% vs. 31.2%)		hours) showed superior	
(PlasmAr)		1			pool of					primary and secondary	
		saline			up to 5					outcomes in the CCP arm	
					donors)					(n= 28) compared to the	
										placebo arm (n=11), but the	
										minimal contribution of this	
										group to the overall cohort	
										(228 CCP and 105 placebo)	
										made the advantage	
										disappear in the final	
										outcomes at day 30 (12).	
NCT04356	40 (1:1)	BSC	n.a.	4 (95%)	200+20	n.a.	n.a.	no difference in	underpowered; the CP	primary outcome measure -	(46)
534				5 (5%)	0			requirement for	group were a higher risk	ventilation – was required in	
(AlQahtani					methyl			ventilation, white	group with higher ferritin	6 controls and 4 patients on	
)					ene			blood cell count,	levels	CCP (risk ratio 0.67 95% CI	
					blue			LDH, C-reactive		0.22 - 2.0, p=0.72); mean	
					inactiva			protein (CRP),		time on ventilation was 10.5	

				ted	t			troponin, ferritin, D-		days in the control against	
								dimer,		8.2 days in patients on CCP	
								procalcitonin,		(p=0.81).	
								mortality rate at 28			
								days			
NCT04346	29 (1:1)	BSC +	< 3 (from	4-5 25	0+25	n.a.	n.a.	no significant	nAb measured with	better median improvement	(57)
446		FFP	symptoms)	0				reduction in	surrogate competitive	in PaO ₂ /FiO ₂ at 48-hours	
(Bajpai)								mortality or	assay (GenScript);	[42 vs 231] and at day 7	
								hospitalization	beneficial factors in FFP		
									used in control arm (90)		
NCT04381	11558	BSC	9 from	4-7 Me	edian	n.a.	35%	no significant	late usage	the risk ratio for patients	(49)
936	(1:1)		symptoms; 2	27	5±75		seronegati	difference in 28-day		randomized within 7 days of	
(RECOVE			from	(81	1%		ve	mortality,		symptom onset was 0.92 in	
RY)			hospitalizati	go	t 2			progression to		favor of CCP versus 1.06 in	
			on	uni	its			invasive		patients randomized later;	
				fro	m			mechanical		0.95 for those randomized	
				dif	feren			ventilation. Closed		within 3 days (personal	
				t				for futility		communication). A	
				do	nors;					reanalysis of seronegative	
				12	%1					patients (having 10% lower	
				uni	it)					mortality) with a vague prior	
										found that the likelihood of	
										any or modest benefit was	
										86-68% (79).	
NCT04348	940 (out of	BSC	8 from	4-6 1-2	2	1:250	n.a.	closed for futility	late usage (hypoxemic),	each standard log increase	(109
656	1200)		symptoms	uni	its			(even in the	sicker CCP arm (more	in neutralization or ADCC)
(CONCOR	(2:1)			ea	ch			subgroup	abnormal CXR, more in	independently reduced the	
-1)				25	0-ml			transfused within 3	ICU), varyng standard of	potential harmful effect of	
								days from	care across 72 centres in	CCP (OR=0.74), while anti-	
								diagnosis) in	3 countries	Spike IgG	
								intubation or death		increased it (OR=1.53)	
								by day 30			

NCT02735	2011	BSC	≤ 3 from ICU	5 (25%)	2 units	≥ 1:80 for	In	no significant	very late usage	In the small number of	
707			hospitalizati	6 (75%)	(550±1	Australia;	Australia;	difference in		participants (n□=□126) with	
(REMAP-			on		50 ml)	≥1:160 in	n.a. in	median organ		immunodeficiency at	
CAP)					within	Canada;	Canada,	support-free		baseline, convalescent	
					48	n.a. in UK	UK, and	days,in-hospital		plasma demonstrated	
					hours	and USA	USA	mortality or median		potential benefit (posterior	
								number of days		probability of superiority of	
								alive and free of		89.8%).	
								organ support at			
								day 21. Closed for			
								futility			
NCT04355	511 (out of	BSC	4 from	2-3	1 250-	1:641 ID ₅₀	n.a.	nonsignificant	'all cause' outcome	9.4% reduction in primary	(27,
767	900) with		symptoms,		ml unit			difference in risk	instead of COVID-19-	event endpoint in CCP	136)
(C3PO)	at least 1		presented to					difference (1.9%).	related outcome;	group, which rises to 24%	
	risk factor		the					Outcomes	centralized CCP supply to	after exclusion on patients	
	associated		emergency					regarding worst	distant sites likely affected	admitted on the index visit	
	with		department					illness severity and	by different SARS-CoV-2	(p =07). Dyspnea	
	severe							hospital-free days	variants (52) (since only 4	emerged in 6.7% of	
	COVID-19							were similar in the	of the 48 centers were in	controls, but in 2.3% of the	
								two groups	Illinois or Colorado, most	CCP treated (P < .05).	
									CCP usage had to be	Hospitalizations (including	
									from remote sources);	deaths) after the day of	
									immunosuppressed	treatment were found in	
									individuals were nearly	12.8% of the CCP treated	
									twice as common in the	but in 19.6% of controls (p	
									treatment group (12.8%	=.035). Symptom worsening	
									vs 6.7%); designed to	after the first day occurred	
									detect an absolute risk	in 34.9% of CCP recipients,	
									difference of 10% in	but in 41.9% of	
									disease progression (135)	controls (p < .05)	
NCT04359	223 (2:1)	BSC +	9 from	5-7	1 200-	1:160	n.a.	at 28 days, no	very late usage; beneficial	lower mortality (12.6% vs.	(11)
810		FFP	symptoms		250 ml			significant	factors in FFP used in	24.6%) compared to	

(O'Donnell					unit			improvement in clinical status	control arm (90)	nonconvalescent plasma	
NCT04381	190 (2:1)	BSC +	12 from	6	2 200-	n.a.	n.a.	no difference in	very late usage; beneficial	none	(137
858		IVIg	symptoms	7 (85%)	ml units	(29.5%		mortality at day 28	factors of IVIg used in)
(Gonzalez)		1.5			24	received at			control arm		
		mg/kg			hours	least 1 unit					
					apart	of CCP					
						with					
						antibodies)					
NCT04344	74 (out of	BSC +	9 from	n.a.	2 200-	1:526	n.a.	no difference in	very late usage; beneficial	all-cause mortality through	(56)
535	500) (4:1)	FFP	symptoms, 4		ml units			ventilator-free days	factors in FFP used in	90 days was numerically	
(Bennett-			from					or mortality (27%	control arm (90)	lower in the CCP versus	
Guerrero)			hospitalizati					vs. 33%) at day 28.		standard plasma groups	
			on					Terminated after		(27% vs 33%; p = 0.63)	
								FDA issued EUA			
NCT04433	105 (1:1)	BSC	7 from	4-7	3 units	1:160	1:160	not significant	moderately late usage	median time to clinical	(51)
910			symptoms		from	(PRNT ₅₀)	(PRNT ₅₀)	difference in the		improvement was 26 days	
(CAPSID)					same			primary outcome		in the CCP group and 66	
					donor			(dichotomous		days in the control group	
					over 5			composite outcome		(p=0.27). Median time to	
					days			of survival and no		discharge from hospital was	
					(850			longer fulfilling		31 days (IQR 16-n.r.) in the	
					ml)			criteria for severe		CCP and 51 days (IQR 20-	
								COVID-19) and		n.r.) in the control group	
								secondary		(p=0.24). In the subgroup	
								outcomes		that received a higher	
										cumulative amount of nAbs	
										the primary outcome	
										occurred in 56.0% (versus	
										32.1%), with a shorter	
										interval to clinical	
										improvement, shorter time	

										to hospital discharge and	
										better survival compared to	
										the control group	
NCT04547	160 (1:1)	BSC	10 from	37% 5-6	2 300-	n.a.	>1:80 in	no difference in 28-	very late usage	none	(138
660			symptom	66% 7	ml		83%	day mortality, days)
(PLACOVI					aliquots			alive, days free of			
D)					2 days			respiratory support,			
					apart,			duration of invasive			
								ventilatory support,			
								inflammatory and			
								other laboratorial			
								markers values on			
								days 3, 7 and 14			
NCT04429	320 (2:1)	BSC	7 from	3-5	2 200-	n.a.	≥1:320	no significant	late usage	none	(33,
854			symptoms		250 ml			improvement			139)
(DAWN-					aliquots			proportion of			
plasma)					within			patients that require			
					12			mechanical			
					hours			ventilation or have			
					followe			died at day 15 or 30			
					d by 2						
					units						
					within						
					36						
					hours						
NCT04589	421 (out of	FFP	≤ 7 from		1 300-	1:386	93%	no difference in	moderately late usage,	effect of CP on hospital	(28)
949 (CoV-	690) (1:1)		symptoms	2	ml unit		seronegati	hospital admission,	low titer, low volume; low	admission or death	
Early; first			(median 5?),	2			ve (21	death or time to	hospitalization rate	was largest in patients with	
20%			≥ 50 years				vaccinated	resolution (OR =	(9.3%), hence not	≤5 days of symptoms (OR	
recruitmen			and ≥1				with 2	0.93), regardless of	powered to esclude a	0.658)	
t			additional				doses, 14	nAb titer	small treatment effet		
aggregate			factor				with 1				

d with the			(outpatients)				dose?)				
first 20%											
of ConV-											
ert RCT)											
NCT04393	417 (1:1)	BSC	> 7 from	4-5	2 200-	1:226	n.a.	no statistically	powered to detect an	trends favoring CCP in	(45)
727			radiological		ml	(each unit		significant	exaggerated 40%	basally seronegatives, P/F	
(TSUNAMI			diagnosis		aliquots	> 1:160)		improvement in	reduction in primary	> 300 mmHg (p = 0.059),	
)					(>90%			progression to	endpoint; underpowered	and recipients of units with	
					amotos			ventilatory support	for subgroup analysis; late	higher nAb titres	
					alen;			or death	usage; unexplained		
					<10%				findings at site 02 (which		
					riboflavi				recruited 40% of patients)		
					n-						
					inactiva						
					ted)						
NCT04600	31 (out of	BSC	< 4 from	5	3 200-	1:116	n.a.	no significant	focusing on patients with	none	(74)
440	100) (1:1)		positive		250 ml	(each unit		difference in	worse clinical course		
(COP20)			NPS		aliquots	> 1:40)		number of days of	(oxygen requiring at day 4		
								oxygen treatment to	since NPS); largely		
								keep SaO2 > 93%	underpowered; more days		
								or mortality at 28	passed since onset of		
								days. Closed for	symtoms to transfusion		
								futility			
NCT04397	80 (1:1)	BSC	6 since	3-5	2 units	n.a.	n.a. (60%	significant benefit	no failure	trends for better WHO8	(88)
757			onset of		on day		seronegati	by clinical severity		scores at day 14 and 28,	
(PennCCP			symptoms, 1		1 from		ve)	score		any use of mechanical	
2)			since		2			and 28-day		ventilation or ECMO,	
			hospitalizati		differen			mortality (26% vs.		duration of mechanical	
			on		t			5%) in patient with		ventilation or ECMO use,	
					donors			a median of 3		and duration of	
								comorbidities		supplemental oxygen use	
								(including			

								immunodeficiency)			
NCT04373	1225 (1:1)	FFP	6 since	1-3	1 250-	n.a.	n.a.	hospitalization in	no failure	none	(29
460	(out of		onset of		ml unit	(1:14,580		6.3% of FFP vs.			
(CSSC-	1344)		symptoms			Euroimmu		2.9% of CCP (RR			
004)			(outpatients)			n)		= 0.46)			
NCT04364	941 (1:1)	BSC +	7 since	5	1 250-	1:93 (70%	n.a. (67%	no improvement in	low-titre (except Q2 and	at day 28, cORs were 0.72	(26
737		placeb	onset of		ml unit	< 1:160)	seropositiv	WHO ordinal scale	Q5) and low volume;	for participants enrolled in	
(CONTAIN		0	symptoms			(1:175	e)	at day 14 or 28	centrally-distributed CCP	Q2 (April-June 2020) and	
)						between			to states with different	0.65 for those not receiving	
						April and			viral variants after June	remdesivir and not receiving	
						June 2020)			2020; primary endpoint	corticosteroids at	
									too early at day 14	randomization. At day 28,	
										mortality was lower in 486-	
										seropositive than 242-	
										seronegative participants	
										irrespective of treatment	
										arm, and in seronegative	
										CCP (14.4%) than placebo	
										(17.9%)	
NCT04323	180 (1:1)	BSC +	exposed	0	1 unit	> 1:320	100%	no reduction in	not powered to show	no COVID-19-related	
300	(out of 500	FFP	within 96 h				seronegati	infection or	reduction in	hospitalizations in CCP and	
CSSC-	because		of				ve	symptomatic	hospitalization	2 in control recipients	
001)	of wide		enrollment					disease rate			
	vaccine		and 120 h of								
	availablity)		receipt of								
			CCP								
			(median 2								
			days)								

* 0: uninfected; no viral RNA detected; 1: asymptomatic; viral RNA detected; 2: symptomatic; independent; 3: symptomatic; assistance needed; 4: hospitalized, no oxygen therapy; 5: hospitalized; oxygen by mask or nasal prongs; 6: hospitalized; oxygen by NIV or high flow; 7: intubation and

676

- 678 mechanical ventilation, pO2/FiO2 \geq 150 or SpO2/FiO2 \geq 200 ; 8 : mechanical ventilation, pO2/FiO2 < 150 (SpO2/FiO2 < 200) or vasopressors; 9 :
- 679 mechanical ventilation pO2/FiO2 < 150 and vasopressors, dialysis or ECMO .

Table 3
Propensity score-matched (PSM) CCP studies reported to date. DPH: days post-hospitalization. None of these studies titered nAbs in either donor or recipient using VNT. HR: hazard ratio; OR: odds ratioL aOR: adjusted OR. aHR: adjusted HR.

study	location	patients+	median days CCP	baseline recipient	transfused CCP	statistically significant outcomes	Reason(s) for failure	(64) All rights (67) reserved. No reuse
design		controls	given post-	WHO score (24)	volume (ml)			l
			hospitalization					1
retrospective	Mount Sinai,	39 + 156	4	5 (87%)	250+250	on day 14 oxygen requirements worsened in 17.9% of	No failure	(64)
	NY, USA			6 (10%)		plasma recipients versus 28.2% of controls (aOR 0.86).		<u>₽</u> = ।
						Survival improved in plasma recipients (aHR 0.34)		- Grit
	Providence,	64 + 177	> 2 (< 10 from onset	4 (70%)	n.a. (2 units)	no significant differences in incidence of in-hospital	Late usage	(67) g
	RI, USA		of symptoms:	5 (30%)		mortality (12.5% and 15.8%; aHR 0.93) or overall rate		Serv
			median 7)			of hospital discharge (RR 1.28, although increased		l ea.
						among patients > 65-years)		ı 2
	Montefiore	90 + 258	< 3 (3-7 days from	5-6 (< 24 hrs	200	anti-S IgG titer ≥1:2,430 (median 1:47,385)	No failure	(63)
	Medical		onset of symptoms)	mechanical		recipients <65 years had 4-fold lower mortality and 4-		Se
	Center, NY,			ventilation)		fold lower deterioration in oxygenation or mortality at		
	USA					day 28		l /eu
	Washington,	263+263	< 14	n.a.	245 (median)	reduced 7-day (9.1 vs. 19.8%) and 14-day mortality	Late usage; control	(69) ≦
	USA					(14.8 vs. 23.6%), but not 28-day mortality (P = 0.06),	cohort was treated, on	ا
						and longer hospital stay	average, 29 days prior to	_
							the CCP cohort	
	USA (176	3774 +	< 3 vs. 4-7	n.a.	n.a.	lower mortality (aHR = 0.71) and faster recovery. CCP	No failure	(70)
	HCA	10687				within 3 days after admission, but not 4-7 days, was		- I
	Healthcare-					associated with a significant reduction in mortality risk		l
	affiliated					(aHR = 0.53). CCP serology level was inversely		l
	community					associated with mortality when controlling for interaction		1
	hospitals)					with days to transfusion (HR = 0.998) but was not		İ
						significant in a univariable analysis		(63) euse allowed winout permission.
	China	163 + 163	23	n.a.	300	hospital stay in CCP group was significantly longer than	Very late usage; more	(140)
						matched control group ($P < 0.0001$).	advanced disease in the	İ

							CCP group (23 days vs. 15 since hospital admission	
	Greece	59 + 59	7	≥4	200-233 ml (days 1, 3, and 5)	significantly reduced risk of death [HR: 0.04, 3.4% vs. 13.6%], significantly better overall survival by Kaplan-Meir analysis, and increased probability of extubation [OR: 30.3]. Higher levels of antibodies (as measured with Euroimmun or pseudoVNT) in CCP were independently associated with significantly reduced risk of death.	No failure	(141)
	New Haven, USA	132 + 2551	< 6 vs > 6 days	moderate to severe		early CCP recipients, of whom 31 (40%) were on mechanical ventilation, had lower 14-day (15% vs 23%) and 30-day (38% vs 49%) mortality compared to a matched unexposed cohort, with nearly 50% lower likelihood of in-hospital mortality (HR 0.52). Early plasma recipients had more days alive and ventilator-free at 30 days (+3.3 days) and improved WHO scores at 7 days (-0.8) and hospital discharge (-0.9) compared to the matched unexposed cohort	No failure	(141) (68) (65)
	USA	143+823 (hematogic al cancer)	n.a.	n.a.	n.a.	improved 30-day mortality (HR, 0.52; 95% CI, 0.29-0.92). Among the 338 patients admitted to the ICU, mortality was significantly lower in CCP recipients compared with nonrecipients (HR 0.40). Among the 227 patients who required mechanical ventilatory support, mortality was significantly lower in CCP recipients compared with nonrecipients (HR 0.32).	No failure	(107)
spective	Houston, USA	136 + 251	n.a.	3 (9%) 4 (63%) 5 (18%) 6 (10%)	300 (1-2 units)	reduction in mortality within 28 days, specifically in patients transfused < 72 hours of admission with CCP with an anti-RBD titer ≥1:1350 (i.e., ~80% probability of a live virus <i>in vitro</i> neutralization titer of ≥1:160 (142))	No failure	(65)
		341 + 594	n.a.	7 (1%)	300 (1-2 units)	reduced 28-day (aHR=2.09 for controls) and 60-day (5.7% vs. 10.7%; aHR=1.82 for controls) mortality in	No failure	(66)

					those transfused with anti-RBD ≥1:1350 within 72 hours		
					post-hospitalization. Optimal window of 44 hours to		
					maximize benefit in 60 days mortality (4% vs 12.3%).		
					91% received CCP with an anti-RBD titer ≥1:1350.		
					median S/CO ratio =24 using Ortho Vitros.		
Poland	102 + 102	n.a.	n.a.	n.a.	lower mortality rate (13.7% vs. 34.3%; OR=0.25)	No falure	(
					related to time of first administration (12.2% at day 5,		
					21.5% at day 10), no significant differences in ICU stay,		
					ventilator time, and hospitalization time. Earlier		
					administration resulted in a ventilator being needed for		
					a shorter length of time $(r = 0.41)$		
Brazil	58+116	6 from onset of	mild and moderate	200 ml	No differences	only 48% CCP units	
	(kidney	symptoms			in the need for supplementary oxygen or mechanical	were high-titer;	
	transplant				ventilation at day 30	compared to	
	recipients)					nonsurvivors, a trend	
						towards a higher	
						proportion of survivors	
						receiving higher-titer	
						CCP	
Colorado (16	188 + 188	n.a.	n.a.	1 unit if < 90 kg; 2	increased length of hospital stay in CCP-treated	Covariate matching not	
hospitals)				units if > 90kg	patients and no change in inpatient mortality compared	achieved for subgroup	
					to controls. In subgroup analysis of CCP-treated	receiving CCP < 3 days	
					patients within 3 or 7 days of admission, there was no		
					difference in length of hospitalization and inpatient		
I					mortality.		

Table 4

685

686

687

Summary of completed but not yet reported or ongoing RCTs of CCP, as registered on ClinicalTrials.gov as of August 26, 2021. BSC: best supportive care;

FFP: fresh frozen plasma. Several studies were withdrawn (NCT04377568).

Status	NCT number	Patient subtype	Control arm	Study design	Number planned to enrol	Studystart	Locations
Completed	NCT04332835	severe (SOFA <6)	BSC	single masking (outcomes assessor)	92	August 8, 2020	Colombia
	NCT04349410	any	10 different arms	single masking (investigator)	1800	April 11, 2020	USA
	NCT04421404 (CAPRI)	within 3 days from hospitalization or 14 from symptoms	placebo	triple masking (participant, care provider, investigator)	34	June 9, 2020	USA
	NCT04374526	pneumonia, age > 65 and PaO2/FiO2 ≥300 mmHg and comorbidities	BSC	open ab el	29	May 27, 2020	Italy
	NCT04358783	hospitalized requiring supplemental oxygen	BSC	quadruple masking (participant, care provider, investigator, outcomes assessor)	30	April 27, 2020	Mexico
	NCT04405310	moderate to severe requiring supplemental oxygen	albu min	double (participant, care provider)	80	May 20, 2020	Mexico
	NCT04425915	on ventilator within 3 days from onset of symptoms	BSC	open ab el	400	June 14, 2020	In di a
Active, not recruiting	NCT04539275	ventilated and within 3 days from hospitalization	masked saline placebo	triple masking (participant, care provider, investigator)	702	November 16, 2020	USA
	N CT04374487	hospitalized and severe	BSC	open ab el	100	May 9, 2020	In di a
	NCT04425837	high-risk	BSC	single masking (outcomes assessor)	236	July 2020	Colombia
	NCT04395170	hospitalized	2 arms (BSC; anti-COVID-19 IVIG)	open label	75	September 2020	Colombia

	NCT04391101	severe	BSC	open label	231	June 2020	Colombia
Recruiting	NCT04516811	moderate to severe	placebo	triple masking (participant, care provider, investigator)	600	September 21, 2020	South Africa
	NCT04388410	hospitalized, severe disease or risk for severe diseases	BSC	quadruple masking (participant, care provider, investigator, outcomes assessor)	410	August 25, 2020	Mexico
	NCT04385043	severe Infection	BSC	open label	400	May 1, 2020	Italy
	NCT04380935	acute respiratory distress syndrome	BSC	open label	60	May 18, 2020	In don esi a
	N CT04362176 (P assIt On)	hospitalized adults	placebo	triple masking (participant, care provider, outcomes assessor)	1000	April 24, 2020	USA
	NCT04390503	exposed within 7 days or mild symptoms within 5 days	albu min	double masking (participant, outcome assessor)	150	March 12, 2021	USA
	NCT04376034	severe or life- threatening	BSC	open label	240	March 30, 2021	USA
	NCT04366245	hospitalized ventilated	BSC	open label	72	April 23, 2020	Spain
	NCT04333251	hospitalized within 7 days from symptoms	BSC	open label	115	April 1, 2020	USA
	NCT04345991	mild and within 8 days from symptoms	BSC	open label	120	April 15, 2020	France
	NCT04372979	hospitalized within 10 days from symptoms	FFP	triple masking (participant, care provider, outcomes assessor)	80	September 14, 2020	France
	NCT04345289	adults with pneumonia	placebo	quadruple masking (participant, care provider, investigator, outcomes assessor)	1100	May 1, 2020	Denmark

References

- Casadevall A, Pirofski LA, Joyner MJ. 2021. The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. mBio 12:e03372-20.
- 691 2. Casadevall A, Pirofski L-a. 2020. The convalescent sera option for containing COVID-19. The Journal of Clinical Investigation 130.
- Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. 2010. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 38:e66-73.
- Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. 2020.
 Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences doi:10.1073/pnas.2004168117:202004168.
- Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z. 2020. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Lifethreatening COVID-19: A Randomized Clinical Trial. JAMA 324:460-470.
- 706 6. Perotti C, Baldanti F, Bruno R, Delfante C, Seminari E, Casari S, Percivalle E, Glingani C, 707 Musella V, Belliato M, Garuti M, Meloni F, Frigato M, Di Sabatino A, Klersy C, De Donno G, 708 Franchini M. 2020. Mortality reduction in 46 severe Covid-19 patients treated with 709 hyperimmune plasma. A proof of concept single arm multicenter interventional trial. 710 Haematologica 105:2834-2840.
- 7. Focosi D, Anderson AO, Tang JW, Tuccori M. 2020. Convalescent Plasma Therapy for COVID-19: State of the Art. Clin Microbiol Rev 33:e00072-20.
- Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, Carter RE, Klompas AM, Wiggins CC, Shepherd JR, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Johnson PW, Lesser ER, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Hodge DO, Kunze KL, Buras MR, Vogt MN, Herasevich V, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, van Buskirk CM, Winters JL, Stubbs JR, Paneth NS, Verdun NC, Marks P, Casadevall A. 2020. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest doi:10.1172/jci140200.
- Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC,
 Bruno KA, Klompas AM, Lesser ER, Kunze KL, Sexton MA, Diaz Soto JC, Baker SE, Shepherd
 JRA, van Helmond N, Verdun NC, Marks P, van Buskirk CM, Winters JL, Stubbs JR, Rea RF,
 Hodge DO, Herasevich V, Whelan ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Buras
 MR, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Paneth NS, Fairweather D, Wright
 RS, Casadevall A. 2021. Convalescent Plasma Antibody Levels and the Risk of Death from
 Covid-19. N Engl J Med 384:1015-1027.
- 726 Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, Latha B, Bundas S, 10. 727 Kumar V, Dosi R, Khambholja JK, de Souza R, Mesipogu RR, Srivastava S, Dube S, Chaudhary 728 K, S S, Mattuvar K SA, Rajendran V, Sundararajaperumal A, Balamanikandan P, Maheswari 729 RSU, Jayanthi R, Ragunanthanan S, Bhandari S, Singh A, Pal A, Handa A, Rankawat G, 730 Kargirwar K, Regi J, Rathod D, Pathrose E, Bhutaka N, Patel MH, Verma RJ, Malukani K, Patel 731 S, Thakur A, Joshi S, Kulkarni R, Suthar NN, Shah NM, Purohit HM, Shah CK, Patel MN, Shah S, 732 Shah SH, Memon T, Beriwala VR, et al. 2020. Convalescent plasma in the management of 733 moderate COVID-19 in India: open-label parallel-arm phase II multicentre randomized 734 controlled trial (PLACID Trial). BMJ 371:m3939.
- 735 11. O'Donnell MR, Grinsztejn B, Cummings MJ, Justman J, Lamb MR, Eckhardt CM, Philip NM, Cheung YK, Gupta V, João E, Pilotto JH, Diniz MP, Cardoso SW, Abrams D, Rajagopalan K, Borden S, Wolf A, Sidi LC, Vizzoni A, Veloso VG, Bitan ZC, Scotto DE, Meyer BJ, Jacobson SD, Kantor A, Mishra N, Chauhan LV, Stone E, Dei Zotti F, La Carpia F, Hudson KE, Ferrera SA,

- Schwartz J, Stotler B, Lin W-H, Wontakal S, Shaz B, Briese T, Hod EA, Spitalnik SL, Eisenberger A, Lipkin WI. 2021. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. J Clin Invest doi:10.1172/JCI150646:150646.
- Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, Savoy N, Giunta DH, Pérez LG, Sánchez MdL, Gamarnik AV, Ojeda DS, Santoro DM, Camino PJ, Antelo S, Rainero K, Vidiella GP, Miyazaki EA, Cornistein W, Trabadelo OA, Ross FM, Spotti M, Funtowicz G, Scordo WE, Losso MH, Ferniot I, Pardo PE, Rodriguez E, Rucci P, Pasquali J, Fuentes NA, Esperatti M, Speroni GA, Nannini EC, Matteaccio A, Michelangelo HG, Follmann D, Lane HC, Belloso WH. 2020. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med 384:619-629.
- 749 13. Pirofski LA, Casadevall A. 2020. Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework. mBio 11.
- Marconato M, Abela IA, Hauser A, Schwarzmueller M, Katzensteiner R, Braun DL, Epp S,
 Audige A, Weber J, Rusert P, Schindler E, Pasin C, West E, Boeni J, Kufner V, Huber M, Zaheri
 M, Schmutz S, Frey BM, Kouyos RD, Gunthard HF, Manz MG, Trkola A. 2021. Contribution of
 endogenous and exogenous antibodies to clearance of SARS-CoV-2 during convalescent
 plasma therapy. doi:10.1101/2021.12.09.21267513 %J medRxiv:2021.12.09.21267513.
- 756 15. Van Rompay KKA, Olstad KJ, Sammak RL, Dutra J, Watanabe JK, Usachenko JL, Immareddy R, Roh JW, Verma A, Lakshmanappa YS, Schmidt BA, Germanio CD, Rizvi N, Stone M, Simmons G, Dumont LJ, Allen AM, Lockwood S, Pollard RE, de Assis RR, Yee JL, Nham PB, Ardeshir A, Deere JD, Patterson J, Jain A, Felgner PL, Iyer SS, Hartigan-O'Connor DJ, Busch MP, Reader JR. 2021. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation. doi:10.1101/2021.09.01.458520 %J bioRxiv:2021.09.01.458520.
- Takamatsu Y, Imai M, Maeda K, Nakajima N, Higashi-Kuwata N, Iwatsuki-Horimoto K, Ito M,
 Kiso M, Maemura T, Takeda Y, Omata K, Suzuki T, Kawaoka Y, Mitsuya H. 2021. Highly
 Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and
 Pneumonia in Syrian Hamsters. J Virol doi:10.1128/jvi.01551-21:Jvi0155121.
- Deere JD, Carroll TD, Dutra J, Fritts L, Sammak RL, Yee JL, Olstad KJ, Reader JR, Kistler A,
 Kamm J, Di Germanio C, Shaan Lakshmanappa Y, Elizaldi SR, Roh JW, Simmons G, Watanabe
 J, Pollard RE, Usachenko J, Immareddy R, Schmidt BA, O'Connor SL, DeRisi J, Busch MP, Iyer
 SS, Van Rompay KKA, Hartigan-O'Connor DJ, Miller CJ. 2021. SARS-CoV-2 Infection of Rhesus
 Macaques Treated Early with Human COVID-19 Convalescent Plasma. Microbiol Spectr
 doi:10.1128/Spectrum.01397-21:e0139721.
- 773 18. Focosi D, Maggi F, Franchini M, Aguzzi A, Lanza M, Mazzoni A, Menichetti F. 2021. Patient-774 blood management for COVID19 convalescent plasma therapy: relevance of affinity and 775 donor-recipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect 776 doi:10.1016/j.cmi.2021.04.003.
- 777 19. Alamgir J, Abid R, Garibaldi BT, Munir N, Setoguchi S, Hong SS, Chen X, Kocis PT, Yajima M, Alexander GC, Mehta HB, Madhira V, Ergas R, O'Brien TR, Bozzette S. 2021. Lack of association between convalescent plasma administration and length of hospital stay: a hospital-day stratified multi-center retrospective cohort study. medRxiv [Preprint] doi:10.1101/2021.05.04.21256627 %J medRxiv:2021.05.04.21256627.
- Kocayiğit H, Demir G, Karacan A, Süner K, Tomak Y, Yaylacı S, Dheir H, Kalpakci Y, Erdem AF.
 2021. Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19. Transfus Apher Sci doi:10.1016/j.transci.2021.103148:103148.
- Focosi D, Navarro D, Maggi F, Roilides E, Antonelli G. 2021. COVID-19 infodemics: the role of mainstream and social media. Clin Microbiol Infect doi:10.1016/j.cmi.2021.08.003.
- 787 22. Harrell F, Lindsell C. 2021. Statistical Design and Analysis Plan for Sequential Parallel-Group RCT for COVID-19.

- 789 23. Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, García Morales MT, Arana-Arri E, Aldea M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J. 2021. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet 398:121-130.
- 795 24. WHO. 2020. R & D Blueprint novel Coronavirus COVID19 Therapeutic Trial Synopsis.
 796 https://www.who.int/blueprint/priority-diseases/key-action/COVID797 19 Treatment Trial Design Master Protocol synopsis Final 18022020.pdf?ua=1.
 798 Accessed October 1.
- 799 25. Anonymous. 2020. A minimal common outcome measure set for COVID-19 clinical research.
 800 Lancet Infect Dis 20:e192-e197.
- 801 26. Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, 802 O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, 803 804 Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, 805 Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, 806 Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, 807 Parameswaran L, et al. 2021. Efficacy and Safety of COVID-19 Convalescent Plasma in 808 Hospitalized Patients: Α Randomized Clinical Trial. **JAMA** Intern Med 809 doi:10.1001/jamainternmed.2021.6850.
- 810 27. Korley FK, Durkalski-Mauldin V, Yeatts SD, Schulman K, Davenport RD, Dumont LJ, El Kassar R11 N, Foster LD, Hah JM, Jaiswal S, Kaplan A, Lowell E, McDyer JF, Quinn J, Triulzi DJ, Van R12 Huysen C, Stevenson VLW, Yadav K, Jones CW, Kea B, Burnett A, Reynolds JC, Greineder CF, R13 Haas NL, Beiser DG, Silbergleit R, Barsan W, Callaway CW. 2021. Early Convalescent Plasma For High-Risk Outpatients with Covid-19. N Engl J Med doi:10.1056/NEJMoa2103784.
- Millat-Martinez P, Gharbharan A, Alemany A, Rokx C, GeurtsvanKessel C, Papageourgiou G, van Geloven N, Jordans C, Groeneveld G, Swaneveld F, van der Schoot E, Corbacho-Monne M, Ouchi D, Ferreira FP, Malchair P, Videla S, Garcia VG, Ruiz-Comellas A, Ramirez-Morros A, Codina JR, Simon RA, Grifols J-R, Blanco J, Blanco I, Ara J, Bassat Q, Clotet B, Baro B, Troxel A, Zwaginga JJ, Mitja O, Rijnders B. 2021. Convalescent plasma for outpatients with early COVID-19. doi:10.1101/2021.11.30.21266810 %J medRxiv:2021.11.30.21266810.
- Sullivan D, Gebo K, Shoham S, Bloch E, Lau B, Shenoy A, Mosnaim G, Gniadek T, Fukuta Y,
 Patel B, Heath S, Levine A, Meisenberg B, Spivak E, Anjan S, Huaman M, Blair J, Currier J,
 Paxton J, Gerber J, Petrini J, Broderick P, Rausch W, Cordisco M, J H, Greenblatt B, Cluzet V,
 Cruser D, Oei K, Abinante M, Hammitt L, Sutcliffe C, Forthal D, Zand M, Cachay E, Raval J,
 Kassaye S, Foster E, Roth M, Marshall C, Yarava A, Lane K, McBee N, Gawad A, Karlen N,
 Singh A, Ford D, Jabs D, Appel L, Shade D, et al. 2021. Randomized Controlled Trial of Early
 Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv.
- 828 30. Shoham S, Bloch EM, Casadevall A, Hanley D, Lau B, Gebo K, Cachay E, Kassaye SG, Paxton 829 JH, Gerber J, Levine AC, Currier J, Patel B, Allen ES, Anjan S, Appel L, Baksh S, Blair PW, 830 Bowen A, Broderick P, Caputo CA, Cluzet V, Cordisco ME, Cruser D, Ehrhardt S, Forthal D, 831 Fukuta Y, Gawad A, Gniadek T, Hammel J, Huaman MA, Jabs DA, Jedlicka A, Karlen N, Klein S, 832 Laeyendecker O, Lane K, McBee N, Meisenberg B, Merlo C, Mosnaim G, Park H-S, Pekosz A, 833 Petrini J, Rausch W, Shade DM, Shapiro J, Singleton JR, Sutcliffe C, Thomas DL, et al. 2021. 834 Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis 835 against SARS-CoV-2 infection. doi:10.1101/2021.12.13.21267611 %J 836 medRxiv:2021.12.13.21267611.
- Focosi D, Mazzetti P, Pistello M, Maggi F. 2020. Viral infection neutralization tests: a focus on SARS-CoV-2 with implications for convalescent plasma therapy. Rev Med Virol 31:e2170.

- 839 32. Nguyen D, Simmonds P, Steenhuis M, Wouters E, Desmecht D, Garigliany M, Romano M, Barbezange C, Maes P, Van Holm B, Mendoza J, Oyonarte S, Fomsgaard A, Lassaunière R, Zusinaite E, Resman Rus K, Avšič-Županc T, Reimerink JH, Brouwer F, Hoogerwerf M, Reusken CB, Grodeland G, Le Cam S, Gallian P, Amroun A, Brisbarre N, Martinaud C, Leparc Goffart I, Schrezenmeier H, Feys HB, van der Schoot CE, Harvala H. 2021. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Euro Surveill 26.
- Devos T, Van Thillo Q, Compernolle V, Najdovski T, Romano M, Dauby N, Jadot L, Leys M, Maillart E, Loof S, Seyler L, Moonen M, Moutschen M, Van Regenmortel N, Ariën KK, Barbezange C, Betrains A, Garigliany M, Engelen MM, Gyselinck I, Maes P, Schauwvlieghe A, Liesenborghs L, Belmans A, Verhamme P, Meyfroidt G. 2021. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J doi:10.1183/13993003.01724-2021.
- 852 34. Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, Annane D, Arabi YM, Arnold DM, Beane A, Bégin P, van Bentum-Puijk W, Berry LR, Bhimani Z, Birchall JE, Bonten MJM, 853 854 Bradbury CA, Brunkhorst FM, Buxton M, Callum JL, Chassé M, Cheng AC, Cove ME, Daly J, 855 Derde L. Detry MA, De Jong M, Evans A, Fergusson DA, Fish M, Fitzgerald M, Foley C, 856 Goossens H, Gordon AC, Gosbell IB, Green C, Haniffa R, Harvala H, Higgins AM, Hills TE, Hoad 857 VC, Horvat C, Huang DT, Hudson CL, Ichihara N, Laing E, Lamikanra AA, Lamontagne F, Lawler 858 PR, Linstrum K, Litton E, et al. 2021. Effect of Convalescent Plasma on Organ Support-Free 859 Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA 326:`1690-860 1702.
- Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FPN, Stalenhoef JE, Dofferhoff A, Ludwig I, Koster A, Hassing R-J, Bos JC, van Pottelberge GR, Vlasveld IN, Ammerlaan HSM, Segarceanu E, Miedema J, van der Eerden M, Papageorgiou G, te Broekhorst P, Swaneveld FH, Katsikis PD, Mueller Y, Okba NMA, Koopmans MPG, Haagmans BL, Rokx C, Rijnders B. 2021. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Comm 12:3189.
- 868 36. Del Fante C, Franchini M, Baldanti F, Percivalle E, Glingani C, Marano G, Mengoli C, Mortellaro C, Viarengo G, Perotti C, Liumbruno GM. 2020. A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations. Transfusion 61:830-838.
- 872 37. Mehew J, Johnson R, Roberts D, Harvala H. 2020. Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020. Euro Surveill 25:2001754.
- Mattiuzzo P, Bentley E, Hassal M, Routley S, Richardson S, Bernasconi V, Kristianse P, Harvala
 H, Roberts D, Semple M, Turtle L, Openshaw P, Baillie K. 2020. Establishment of the WHO
 International Standard and Reference Panel for Anti-SARS-CoV-2 Antibody; WHO Expert
 Committee on Biological Standardization: Geneva, Switzerland (2020) WHO/BS/2020.2403.
- 879 39. Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, Ikegame S, Hung C-T, Enyindah-880 Asonye G, Amanat F, Baine I, Arinsburg S, Bandres JC, Kojic EM, Stoever J, Jurczyszak D, 881 Bermudez-Gonzalez M, Simon V, Nádas A, Liu S, Lee B, Krammer F, Zolla-Pazner S, Hioe CE. 882 2020. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. J Infect Dis 883 223:957-970.
- 884 40. Egloff SAA, Junglen A, Restivo JSA, Wongskhaluang M, Martin C, Doshi P, Schlauch D, Fromell G, Sears LE, Correll M, Burris HA, LeMaistre CF. 2021. Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J Clin Invest doi:10.1172/JCl151788.
- Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, Bloch EM, Littlefield K, Wieland-Alter W, Connor RI, Wright PF, Benner SE, Bonny TS, Laeyendecker O, Sullivan D, Shoham S, Quinn

- TC, Larman HB, Casadevall A, Pekosz A, Redd AD, Tobian AAR, Ackerman ME. 2021. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. mBio 12.
- Focosi D, Franchini M. 2021. Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency. Transfus Clin Biol 28:132-134.
- 894 43. Bojadzic D, Alcazar O, Buchwald P. 2021. Methylene Blue Inhibits the SARS-CoV-2 Spike— 895 ACE2 Protein-Protein Interaction—a Mechanism that can Contribute to its Antiviral Activity 896 Against COVID-19. 11.
- 897 44. Ross V. 1938. Photodynamic Action of Methylene Blue on Antipneumococcal Serum. 898 35:351-369.
- 899 Menichetti F, Popoli P, Puopolo M, Spila Alegiani S, Tiseo G, Bartoloni A, De Socio G, Luchi S, 45. 900 Blanc P, Puoti M, De Donno G, Toschi E, Massari M, Palmisano L, Marano G, Chiamenti M, 901 Martinelli L, Franchi S, Pallotto C, Suardi L, Luciani Pasqua B, Merli M, Fabiani P, Bertolucci L, 902 Borchi B, Modica S, Moneta S, Marchetti G, d'Arminio Monforte A, Stoppini L, Ferracchiato 903 N, Piconi S, Fabbri C, Beccastrini E, Saccardi R, Giacometti A, Esperti S, Pierotti P, Bernini I, 904 Bianco C, Benedetti S, Lanzi A, Bonfanti P, Massari M, Sani S, Saracino A, Castagna A, Trabace l, Lanza M, Focosi D, et al. 2021. Effect of High-Titer Convalescent Plasma on Progression to 905 906 Severe Respiratory Failure or Death in Hospitalized Patients with COVID-19 Pneumonia: A 907 Randomized Clinical Trial. Submitted 4:e2136246.
- 46. AlQahtani M, Abdulrahman A, Almadani A, Alali SY, Al Zamrooni AM, Hejab AH, Conroy RM,
 Wasif P, Atkin SL, Otoom S, Abduljalil M. 2020. Randomized controlled trial of convalescent
 plasma therapy against standard therapy in patients with severe COVID-19 disease. Sci Rep
 11:9927.
- 912 47. Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, Ruiz-Antoran B, Malo de Molina R, 913 Torres F, Fernandez-Cruz A, Callejas-Diaz A, Calderon J, Payares-Herrera C, Salcedo I, Romera 914 I, Lora-Tamayo J, Mancheno-Losa M, Paciello ML, Villegas C, Estrada V, Saez-Serrano I, 915 Porras-Leal ML, Jarilla-Fernandez MdC, Pano-Pardo JR, Moreno-Chulilla JA, Arrieta-Aldea I, 916 Bosch A, Belhassen-Garcia M, Lopez-Villar O, Ramos-Garrido A, Blanco L, Madrigal ME, 917 Contreras E, Muniz-Diaz E, Domingo-Morera JM, Casas-Flecha I, Perez-Olmeda M, Garcia-918 Perez J, Alcami J, Bueno JL, Duarte RF. 2021. A multicenter randomized open-label clinical 919 trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest 920 doi:10.1172/JCl152740:152740.
- 921 48. Raster J, Zimmermann K, Wesche J, Aurich K, Greinacher A, Selleng K. 2021. Effect of
 922 Methylene Blue Pathogen Inactivation on the Integrity of Immunoglobulin M and G.
 923 Transfusion Medicine and Hemotherapy 48:148-153.
- 49. Horby PW, Estcourt L, Peto L, Emberson JR, Staplin N, Spata E, Pessoa-Amorim G, Campbell M, Roddick A, Brunskill NE, George T, Zehnder D, Tiberi S, Aung NN, Uriel A, Widdrington J, Koshy G, Brown T, Scott S, Baillie JK, Buch MH, Chappell LC, Day JN, Faust SN, Jaki T, Jeffery K, Juszczak E, Lim WS, Montgomery A, Mumford A, Rowan K, Thwaites G, Mafham M, Roberts D, Haynes R, Landray MJ. 2021. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
 930 Lancet 397:2049-2059.
- 931 50. Bahnan W, Wrighton S, Sundwall M, Bläckberg A, Larsson O, Höglund U, Khakzad H, Godzwon M, Walle M, Elder E, Happonen L, André O, Kumra Ahnlide J, Hellmark T, Wendel-Hansen V, Wallin RP, Malmström J, Malmström L, Ohlin M, Rasmussen M, Nordenfelt P. 2021. Opsonization by non-neutralizing antibodies can confer protection to SARS-CoV-2 despite Spike-dependent modulation of phagocytosis. doi:10.1101/2021.10.14.464464 %J bioRxiv:2021.10.14.464464.
- Spieth P, Lepper PM, Bentz M, Zinn S, Paul G, Kalbhenn J, Dollinger M, Rosenberger P, Kirschning T, Thiele T, Appl T, Mayer B, Schmidt M, Drosten C, Wulf H, Kruse JM, Jungwirth B, Seifried E, Schrezenmeier H. 2021. Results of the CAPSID randomized trial for high-dose

- 941 convalescent plasma in severe COVID-19 patients. J Clin Invest doi:10.1172/JCI152264:2021.05.10.21256192.
- 943 52. Kunze KL, Johnson PW, van Helmond N, Senefeld JW, Petersen MM, Klassen SA, Wiggins CC, 944 Klompas AM, Bruno KA, Mills JR, Theel ES, Buras MR, Golafshar MA, Sexton MA, Diaz Soto JC, 945 Baker SE, Shepherd JRA, Verdun NC, Marks P, Paneth NS, Fairweather D, Wright RS, van 946 Buskirk CM, Winters JL, Stubbs JR, Senese KA, Pletsch MC, Buchholtz ZA, Rea RF, Herasevich 947 V, Whelan ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Lesser ER, Vogt MNP, Dennis JJ, 948 Regimbal RJ, Bauer PR, Blair JE, Casadevall A, Carter RE, Joyner MJ. 2021. Mortality in 949 individuals treated with COVID-19 convalescent plasma varies with the geographic 950 provenance of donors. Nat Commun 12:4864.
- 951 53. Rochman ND, Wolf YI, Faure G, Mutz P, Zhang F, Koonin EV. 2021. Ongoing global and regional adaptive evolution of SARS-CoV-2. Proc Natl Acad Sci U S A 118.
- 953 54. Focosi D, Tuccori M, Baj A, Maggi F. 2021. SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses 13.
- 956 55. Junker D, Dulovic A, Becker M, Wagner TR, Kaiser PD, Traenkle B, Rothbauer U, Kienzle K, 957 Bunk S, Strümper C, Häberle H, Schmauder K, Malek N, Althaus K, Koeppen M, Bitzer M, 958 Göpel S, Schneiderhan-Marra N. 2021. Reduced serum neutralization capacity against SARS-959 CoV-2 variants in multiplex ACE2 **RBD** a competition assay 960 doi:10.1101/2021.08.20.21262328, p 2021.08.20.21262328.
- Bennett-Guerrero E, Romeiser JL, Talbot LR, Ahmed T, Mamone LJ, Singh SM, Hearing JC,
 Salman H, Holiprosad DD, Freedenberg AT, Carter JA, Browne NJ, Cosgrove ME, Shevik ME,
 Generale LM, Andrew MA, Nachman S, Fries BC. 2021. Severe Acute Respiratory Syndrome
 Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019
 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial. Crit Care Med
 doi:10.1097/ccm.000000000000005066.
- 967 57. Bajpai M, Kumar S, Maheshwari A, Chhabra K, kale P, Gupta A, Narayanan A, Gupta E, Trehanpati N, Bihari C, Agarwal R, Gupta K, Gupta Uk, Bhardwaj A, Kumar G, Islam M, Singh R, Yadav P, Maiwall R, Sarin SK. 2020. Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial. medRxiv [Preprint] doi:10.1101/2020.10.25.20219337 %J medRxiv:2020.10.25.20219337.
- 972 58. Group RC, Horby PW, Mafham M, Peto L, Campbell M, Pessoa-Amorim G, Spata E, Staplin N, Emberson JR, Prudon B, Hine P, Brown T, Green CA, Sarkar R, Desai P, Yates B, Bewick T, Tiberi S, Felton T, Baillie JK, Buch MH, Chappell LC, Day JN, Faust SN, Jaki T, Jeffery K, Juszczak E, Lim WS, Montgomery A, Mumford A, Rowan K, Thwaites G, Weinreich DM, Haynes R, Landray MJ. 2021. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. doi:10.1101/2021.06.15.21258542 %J medRxiv:2021.06.15.21258542.
- 979 59. Anonymous. 2020. Dexamethasone in Hospitalized Patients with Covid-19. 384:693-704.
- 980 60. Senefeld JW, Johnson PW, Kunze KL, van Helmond N, Klassen SA, Wiggins CC, Bruno KA, Golafshar MA, Petersen MM, Buras MR, Klompas AM, Sexton MA, Diaz Soto JC, Baker SE, 981 982 Shepherd JRA, Verdun NC, Marks P, van Buskirk CM, Winters JL, Stubbs JR, Rea RF, 983 Herasevich V, Whelan ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Vogt MNP, Dennis 984 JJ, Regimbal RJ, Bauer PR, Blair JE, Wright K, Greenshields JT, Paneth NS, Fairweather D, 985 Wright RS, Casadevall A, Carter RE, Joyner MJ. 2021. Program and patient characteristics for 986 the United States Expanded Access Program to COVID-19 convalescent plasma. medRxiv 987 [Preprint] doi:10.1101/2021.04.08.21255115 %J medRxiv:2021.04.08.21255115.
- Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC, Bruno KA,
 Klompas AM, Lesser ER, Kunze KL, Sexton MA, Diaz Soto JC, Baker SE, Shepherd JRA, van
 Helmond N, van Buskirk CM, Winters JL, Stubbs JR, Rea RF, Hodge DO, Herasevich V, Whelan
 ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Buras MR, Vogt MNP, Dennis JJ, Regimbal

- 992 RJ, Bauer PR, Blair JE, Paneth NS, Fairweather D, Wright RS, Carter RE, Casadevall A. 2020. 993 Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: 994 Initial Three-Month Experience. medRxiv [Preprint] doi:10.1101/2020.08.12.20169359 %J 995 medRxiv:2020.08.12.20169359.
- 996 62. Gonzalez SE, Regairaz L, Salazar M, Ferrando N, Gonzalez V, Carrera Ramos P, Pesci S, Vidal JM, Kreplak N, Estenssoro E. 2021. Timing of Convalescent plasma administration and 28-day mortality for COVID-19 pneumonia. doi:10.1101/2021.02.02.21250758 %J medRxiv:2021.02.02.21250758.
- 1000 63. Yoon Ha, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz RH, Wirchnianski AS, Paroder M, 1001 Fehn K, Serrano-Rahman L, Babb R, Sarwar UN, Haslwanter D, Laudermilch E, Florez C, 1002 Dieterle ME, Jangra RK, Fels JM, Tong K, Mariano MC, Vergnolle O, Georgiev GI, Herrera NG, 1003 Malonis RJ, Quiroz JA, Morano NC, Krause GJ, Sweeney JM, Cowman K, Allen S, Annam J, 1004 Applebaum A, Barboto D, Khokhar A, Lally BJ, Lee A, Lee M, Malaviya A, Sample R, Yang XA, 1005 Li Y, Ruiz R, Thota R, Barnhill J, Goldstein DY, Uehlinger J, Garforth SJ, Almo SC, Lai JR, Gil MR, 1006 et al. 2021. Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC. JCI 1007 Insight doi:10.1172/jci.insight.142270:142270.
- Liu STH, Lin H-M, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P,
 Bassily-Marcus A, Bander J, Sanky C, Dupper A, Zheng A, Nguyen FT, Amanat F, Stadlbauer D,
 Altman DR, Chen BK, Krammer F, Mendu DR, Firpo-Betancourt A, Levin MA, Bagiella E,
 Casadevall A, Cordon-Cardo C, Jhang JS, Arinsburg SA, Reich DL, Aberg JA, Bouvier NM. 2020.
 Convalescent plasma treatment of severe COVID-19: a propensity score–matched control
 study. Nature Medicine 26:1708-1713.
- Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, Lopez BV, Eagar TN, Yi X,
 Zhao P, Rogers J, Shehabeldin A, Joseph D, Leveque C, Olsen RJ, Bernard DW, Gollihar J,
 Musser JM. 2020. Treatment of Coronavirus Disease 2019 Patients with Convalescent
 Plasma Reveals a Signal of Significantly Decreased Mortality. Am J Pathol 190:2290-2303.
- 1018 66. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, Lopez BV, Eagar TN, Yi X, 1019 Zhao P, Rogers J, Shehabeldin A, Joseph D, Masud F, Leveque C, Olsen RJ, Bernard DW, 1020 Gollihar J, Musser JM. 2021. Significantly Decreased Mortality in a Large Cohort of 1021 Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma 1022 Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 1023 Spike Protein IgG. Am J Pathol 191:90-107.
- 1024 67. Rogers R, Shehadeh F, Mylona EK, Rich J, Neill M, Touzard-Romo F, Geffert S, Larkin J, Bailey
 1025 JA, Lu S, Sweeney J, Mylonakis E. 2020. Convalescent plasma for patients with severe COVID 1026 19: a matched cohort study. Clin Infect Dis ciaa1548:Epub ahead of print.
- 1027 68. Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng 1028 Y, Hendrickson JE, Tormey CA, Desruisseaux MS. 2021. Early but not late convalescent 1029 plasma is associated with better survival in moderate-to-severe COVID-19. PLoS One 1030 16:e0254453.
- 1031 69. Shenoy AG, Hettinger AZ, Fernandez SJ, Blumenthal J, Baez V. 2021. Early mortality benefit with COVID-19 convalescent plasma: a matched control study. Br J Haematol doi:10.1111/bjh.17272.
- 70. Arnold Egloff SA, Junglen A, Restivo JSA, Wongskhauluang M, Martin C, Doshi P, Schlauch D, Fromell G, Sears LE, Correll M, Burris HA, LeMaistre CF. 2021. Association of Convalescent Plasma Treatment with Reduced Mortality and Improved Clinical Trajectory in Patients Hospitalized with COVID-19 in the Community Setting. doi:10.1101/2021.06.02.21258190 %J medRxiv:2021.06.02.21258190.
- 1039 71. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, Esteban I, Caballero MT,
 1040 Wood C, Berrueta M, Rondan A, Lescano G, Cruz P, Ritou Y, Fernández Viña V, Álvarez Paggi
 1041 D, Esperante S, Ferreti A, Ofman G, Ciganda Á, Rodriguez R, Lantos J, Valentini R, Itcovici N,
 1042 Hintze A, Oyarvide ML, Etchegaray C, Neira A, Name I, Alfonso J, López Castelo R, Caruso G,

- Rapelius S, Alvez F, Etchenique F, Dimase F, Alvarez D, Aranda SS, Sánchez Yanotti C, De Luca J, Jares Baglivo S, Laudanno S, Nowogrodzki F, Larrea R, Silveyra M, Leberzstein G, Debonis A, Molinos J, González M, Perez E, et al. 2021. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med 384:610-618.
- 1047 72. Ray Y, Paul SR, Bandopadhyay P, D'Rozario R, Sarif J, Lahiri A, Bhowmik D, Vasudevan JS, 1048 Maurya R, Kanakan A, Sharma S, Kumar M, Singh P, Roy R, Chaudhury K, Maiti R, Bagchi S, 1049 Maiti A, Perwez MM, Mondal A, Tewari A, Mandal S, Roy A, Saha M, Biswas D, Maiti C, 1050 Chakraborty S, Sarkar BS, Haldar A, Saha B, Sengupta S, Pandey R, Chatterjee S, Bhattacharya 1051 P, Paul S, Ganguly D. 2020. Clinical and immunological benefits of convalescent plasma 1052 therapy in severe COVID-19: insights from a single center open label randomised control 1053 trial. medRxiv [Preprint] doi:10.1101/2020.11.25.20237883 1054 medRxiv:2020.11.25.20237883.
- 1055 73. Epstein J, Burnouf T. 2020. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang 115:485-487.
- 1057 74. Holm K, Lundgren M, Kjedlsen-Kragh J, Ljungquist O, Bottiger B, Wiken C, Oberg J, Fernstrom
 1058 N, Rosendal E, Overby A, Bystrom J, Forsell M, Landin-Olsson M, Rasmussen M. 2021.
 1059 Convalescent plasma treatment of COVID-19: Results from a prematurely terminated
 1060 randomized controlled open-label study in Southern Sweden. BMC Research Note 14:440.
- Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, Grossman BJ,
 Henderson JP, Musser J, Salazar E, Hartman WR, Bouvier NM, Liu STH, Pirofski LA, Baker SE,
 van Helmond N, Wright RS, Fairweather D, Bruno KA, Wang Z, Paneth NS, Casadevall A,
 Joyner MJ. 2021. The Effect of Convalescent Plasma Therapy on Mortality Among Patients
 With COVID-19: Systematic Review and Meta-analysis. Mayo Clin Proc 96:1262-1275.
- 1066 76. Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, Smith ER, Haber NA, 1067 Khanna N, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG. 2021. Association of 1068 Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A 1069 Systematic Review and Meta-analysis. JAMA 325:1185-1195.
- 1070 77. Piechotta V, Iannizzi C, Chai KL, Valk SJ, Kimber C, Dorando E, Monsef I, Wood EM, Lamikanra
 1071 AA, Roberts DJ, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. 2021. Convalescent plasma
 1072 or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
 1073 Cochrane Database Syst Rev 5:Cd013600.
- 1074 78. Axfors C, Janiaud P, Schmitt AM, Van't Hooft J, Smith ER, Haber NA, Abayomi A, Abduljalil M, 1075 Abdulrahman A, Acosta-Ampudia Y, Aguilar-Guisado M, Al-Beidh F, Alejandria MM, Alfonso 1076 RN, Ali M, AlQahtani M, AlZamrooni A, Anaya JM, Ang MAC, Aomar IF, Argumanis LE, 1077 Averyanov A, Baklaushev VP, Balionis O, Benfield T, Berry S, Birocco N, Bonifacio LB, Bowen 1078 AC, Bown A, Cabello-Gutierrez C, Camacho B, Camacho-Ortiz A, Campbell-Lee S, Cao DH, 1079 Cardesa A, Carnate JM, Castillo GJJ, Cavallo R, Chowdhury FR, Chowdhury FUH, Ciccone G, 1080 Cingolani A, Climacosa FMM, Compernolle V, Cortez CFN, Costa Neto A, D'Antico S, Daly J, 1081 Danielle F, et al. 2021. Association between convalescent plasma treatment and mortality in 1082 COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. 1083 BMC Infect Dis 21:1170.
- 1084 79. Hamilton FW, Lee TC, Arnold DT, Lilford RJ, Hemming K. 2021. Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomised controlled trial. Int J Infect Dis S1201-9712:00523-3.
- 1087 80. Cruciani M, Bongiovanni G, Franchini M. 2021. High-titer convalescent plasma therapy for coronavirus disease 2019 and mortality. Transfusion 61:1988-1990.
- 1089 81. Klassen SA, Senefeld JW, Senese KA, Johnson PW, Wiggins CC, Baker SE, van Helmond N, 1090 Bruno KA, Pirofski LA, Shoham S, Grossman BJ, Henderson JP, Wright RS, Fairweather D, 1091 Paneth NS, Carter RE, Casadevall A, Joyner MJ. 2021. Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Front Med (Lausanne) 8:684151.

- 1093 82. Casadevall A, Grossman BJ, Henderson JP, Joyner MJ, Paneth NS, Pirofski LA, Shoham S.
 1094 2021. Please Reevaluate the Data on Convalescent Plasma for COVID-19.
 1095 https://www.medpagetoday.com/opinion/second-opinions/94256?xid=nl mpt DHE 2021-1096
- 1097 30&eun=g1783322d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%
 1098 20Headlines%20Top%20Cat%20HeC%20%202021-08-30&utm_term=NL_Daily_DHE_dual1099 gmail-definition. Accessed August 31, 2021.
- 1100 83. Agarwal A, Rochwerg B, Siemieniuk RA, Agoritsas T, Lamontagne F, Askie L, Lytvyn L, Leo Y-S, 1101 Macdonald H, Zeng L, Amin W, Burhan E, Bausch FJ, Calfee CS, Cecconi M, Chanda D, Du B, 1102 Geduld H, Gee P, Harley N, Hashimi M, Hunt B, Kabra SK, Kanda S, Kim Y-J, Kissoon N, 1103 Kwizera A, Mahaka I, Manai H, Mino G, Nsutebu E, Preller J, Pshenichnaya N, Qadir N, 1104 Sabzwari S, Sarin R, Shankar-Hari M, Sharland M, Shen Y, Ranganathan SS, Souza JP, 1105 Stegemann M, De Sutter A, Ugarte S, Venkatapuram S, Dat VQ, Vuyiseka D, Wijewickrama A, 1106 Maguire B, Zeraatkar D, et al. 2020. A living WHO guideline on drugs for covid-19. 1107 370:m3379.
- 1108 84. Schrezenmeier H, de Angelis V, Bégué S, Cannata L, Erikstrup C, Escourt L, Feys H, Hartmann 1109 C, Lembo M, Mori G, Roberts D, van der Schoot E, Thijssen-Timmer D, Tiberghien P. 2021. 1110 be COVID-19 convalescent plasma should further investigated! 1111 https://www.bmj.com/content/370/bmj.m3379/rapid-responses. Accessed December 21, 1112 2021.
- de Candia P, Prattichizzo F, Garavelli S, La Grotta R, De Rosa A, Pontarelli A, Parrella R, Ceriello A, Matarese G. 2021. Effect of time and titer in convalescent plasma therapy for COVID-19. iScience doi:10.1016/j.isci.2021.102898:102898.
- 1116 86. Kloypan C, Saesong M, Sangsuemoon J, Chantharit P, Mongkhon P. 2021. Convalescent 1117 Plasma for COVID-19: A Meta-analysis of Clinical Trials and Real-World Evidence. Eur J Clin 1118 Invest doi:10.1111/eci.13663:e13663.
- Franchini M, Focosi D, Corsini F, Cruciani M. 2021. Safety and efficacy of convalescent plasma in COVID-19: an overview of systematic reviews. Diagnostics 11:1663.
- 1121 88. Bar K, Shaw P, Choi G, Aqui N, Fesnak A, Yang J, Soto-Calderon H, Grajales L, Starr J,
 1122 Andronov M, Mastellone M, Amonu C, Feret G, DeMarshall M, Buchanan M, Caturla M,
 1123 Gordon J, Wanicur A, Monroy M, Mampe FL, E, Gouma S, Mullin A, Barilla H, Pronina A, Irwin
 1124 L, Thomas R, Eichinger R, Demuth F, Prak E, Pascual J, Short W, Elovitz M, Baron J, Meyer N,
 1125 Degnan K, Frank I, Hensley S, Siegel D, Tebas P. 2021. A Randomized, Controlled Study of
 1126 Convalescent Plasma for Individuals Hospitalized with COVID-19 Pneumonia. J Clin Invest
 1127 131:e155114.
- 1128 89. Anonymous. 2021. Continuous Monitoring of Pooled International Trials of Convalescent
 1129 Plasma for COVID-19 Hospitalized Patients. <a href="https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/research/continuous-institutes/population-health/divisions-sections-centers/biostatistics/population-health/divisions-centers/biostatistics/population-health/divisions-cent
- 1133 90. Focosi D, Franchini M, Pirofski L-a, Burnouf T, Fairweather D, Joyner MJ, Casadevall A. 2021.
 1134 COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of
 1135 Potential Beneficial and Detrimental Co-Factors. Viruses 13:1594.
- 1136 91. Franchini M, Cruciani M. 2021. How Safe Is COVID-19 Convalescent Plasma? Mayo Clin Proc 1137 96:2279-2281.
- Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, Wiggins CC, Senefeld JW, Klompas AM, Hodge DO, Shepherd JR, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Buras MR, Vogt MN, Herasevich V, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, van buskirk CM, Winters JL, Stubbs JR, van Helmond N, Butterfield BP,
- 1142 Sexton M, Diaz Soto J, Paneth NS, Verdun NC, Marks P, Casadevall A, Fairweather D, Carter

- 1143 RE, Wright RS. 2020. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clinic Proceedings 95:1888-95.
- 1145 93. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. 2020. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nature Microbiology 5:1185-1191.
- 1147 94. Focosi D, Novazzi F, Genoni A, Dentali F, Dalla Gasperina D, Baj AM, F. 2021. Emergence of SARS-CoV-2 Spike Escape Mutation Q493R After Treatment for COVID-19. Emerg Infect Dis 27.
- Guigon A, Faure E, Lemaire C, Chopin M, Tinez C, Assaf A, Lazrek M, Hober D, Bocket L, Engelmann I, Kazali Alidjinou E. 2021. Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance. J Infect S0163-4453:00435-7.
- Jensen B, Luebke N, Feldt T, Keitel V, Brandenburger T, Kindgen-Milles D, Lutterbeck M,
 Freise NF, Schoeler D, Haas R, Dilthey A, Adams O, Walker A, Timm J, Luedde T. 2021.
 Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients
 treated with bamlanivimab in Germany. The Lancet Regional Health Europe 8.
- Pommeret F, Colomba J, Bigenwald C, Laparra A, Bockel S, Bayle A, Michot JM, Hueso T, Albiges L, Tiberghien P, Marot S, Jary A, Lacombe K, Barlesi F, Griscelli F, Colomba E. 2021.
 Bamlanivimab+ etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies. Annals of Oncology doi:10.1016/j.annonc.2021.07.015.
- 1163 98. Focosi D, Franchini M. 2021. Potential use of convalescent plasma for SARS-CoV-2 1164 prophylaxis and treatment in immunocompromised and vulnerable populations. Expert Rev 1165 Vaccines doi:10.1080/14760584.2021.1932475:1-8.
- Anonymous. 2021. CoVlg-19 Plasma Alliance Announces Topline Results from NIH Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine.
 <a href="https://www.takeda.com/newsroom/newsreleases/2021/covig-19-plasma-alliance-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigational-covid-19-announces-topline-results-from-nih-sponsored-clinical-trial-of-investigation-clinical-tri
- hyperimmune-globulin-medicine/. Accessed April 2, 2021.
- 1171 100. Anonymous. 2020. ACTIV-3/TICO LY-CoV555 Study Group. A Neutralizing Monoclonal 1172 Antibody for Hospitalized Patients with Covid-19. N Engl J Med 384:905-914.
- 101. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, Perry R, Boscia J,
 1174 Heller B, Morris J, Crystal C, Igbinadolor A, Huhn G, Cardona J, Shawa I, Kumar P, Adams AC,
 1175 Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE,
 1176 Kallewaard NL, Sabo J, Patel DR, Dabora MC, Klekotka P, Shen L, Skovronsky DM. 2021.
 1177 Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N Engl J Med 385:1382-1392.
- 1178 102. Oladunjoye O, Gallagher M, Wasser T, Oladunjoye A, Paladugu S, Donato A. 2021. Mortality 1179 due to COVID-19 infection: A comparison of first and second waves. J Community Hosp 1180 Intern Med Perspect 11:747-752.
- 103. Casadevall A, Dragotakes Q, Johnson PW, Senefeld JW, Klassen SS, Wright SR, Joyner MJ, Paneth N, Carter R. 2021. Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Convalescent Plasma Hesitancy cost lives? Elife 4:e69866.
- 1185 104. Focosi D, Franchini M. 2021. COVID-19 convalescent plasma therapy: hit fast, hit hard! . Vox 1186 Sang.
- 1187 105. Focosi D, Franchini M. 2021. COVID-19 neutralizing antibody-based therapies in humoral 1188 immune deficiencies: A narrative review. Transfus Apher Sci 1189 doi:10.1016/j.transci.2021.103071:103071.
- 1190 106. Senefeld JW, Klassen SA, Ford SK, Senese KA, Wiggins CC, Bostrom BC, Thompson MA, Baker 1191 SE, Nicholson WT, Johnson PW, Carter RE, Henderson JP, Hartman WR, Pirofski LA, Wright 1192 RS, Fairweather L, Bruno KA, Paneth NS, Casadevall A, Joyner MJ. 2021. Use of convalescent
- plasma in COVID-19 patients with immunosuppression. Transfusion 61:2503-2511.

- 107. Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL. 2021. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol doi:10.1001/jamaoncol.2021.1799.
- 1199 108. Casadevall A, Henderson J, Joyner M, Pirofski L-a. 2021. SARS-Cov2 variants and convalescent plasma: reality, fallacies, and opportunities. The Journal of Clinical Investigation doi:10.1172/JCl148832.
- 1202 109. Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, Zeller MP, Beaudoin-Bussières 1203 G, Amorim L, Bazin R, Loftsgard KC, Carl R, Chassé M, Cushing MM, Daneman N, Devine DV, 1204 Dumaresq J, Fergusson DA, Gabe C, Glesby MJ, Li N, Liu Y, McGeer A, Robitaille N, Sachais BS, 1205 Scales DC, Schwartz L, Shehata N, Turgeon AF, Wood H, Zarychanski R, Finzi A, Marceau D, 1206 Huang A, Carr H, Lin Y, Lall R, Graham C, Arsenault C, Sales V, Sidhu D, Semret M, Hamm C, 1207 Arhanchiague E, Solh Z, Srour N, Soliman K, Yee C, Laroche V, Nahirniak S, et al. 2021. 1208 Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized 1209 controlled trial. Nature Medicine doi:10.1038/s41591-021-01488-2.
- 1210 110. Chalmers TC, Matta RJ, Smith H, Jr., Kunzler AM. 1977. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 297:1091-1212 6.
- 1213 111. Vickers MA, Sariol A, Leon J, Ehlers A, Locher AV, Dubay KA, Collins L, Voss D, Odle AE, Holida
 1214 M, Merrill AE, Perlman S, Knudson CM. 2021. Exponential increase in neutralizing and spike
 1215 specific antibodies following vaccination of COVID-19 convalescent plasma donors.
 1216 Transfusion 61:2099-2106.
- 1217 112. Schmidt F, Weisblum Y, Rutkowska M, Poston D, Da Silva J, Zhang F, Bednarski E, Cho A,
 1218 Schaefer-Babajew DJ, Gaebler C, Caskey M, Nussenzweig MC, Hatziioannou T, Bieniasz PD.
 1219 2021. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature
 1220 doi:10.1038/s41586-021-04005-0.
- 113. Germanio CD, Simmons G, Thorbrogger C, Martinelli R, Stone M, Gniadek T, Busch MP. 2021.

 1222 Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and Neutralizing

 1223 Antibodies Against SARS-CoV-2 Variants. doi:10.1101/2021.10.28.21265622 %J

 1224 medRxiv:2021.10.28.21265622.
- 114. Sheffield WP, Bhakta V, Howell A, Jenkins C, Serrano K, Johnson N, Lin Y-CJ, Colwill K, Rathod
 B, Greenberg B, Gingras A-C, Evans DH, Flaumenhaft E, Beckett A, Drews SJ, Devine DV.
 Retention of hemostatic and immunological properties of frozen plasma and COVID-19
 convalescent apheresis fresh-frozen plasma produced and freeze-dried in Canada. n/a.
- 1229 115. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, Metzler M, Kohmer N, 1230 Hoehl S, Helfritz FA, Wolf T, Goetsch U, Ciesek S. 2021. Reduced Neutralization of SARS-CoV-1231 Omicron Variant by Vaccine Sera and monoclonal antibodies. 1232 doi:10.1101/2021.12.07.21267432 %J medRxiv:2021.12.07.21267432.
- 116. Cao YR, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X, Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS. 2021. B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. doi:10.1101/2021.12.07.470392 %J bioRxiv:2021.12.07.470392.
- 1238 117. Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. 2021. ANALYSIS OF IMMUNE 1239 ESCAPE VARIANTS FROM ANTIBODY-BASED THERAPEUTICS AGAINST COVID-19. 1240 doi:10.1101/2021.11.11.21266207 %J medRxiv:2021.11.11.21266207.
- 1241 118. Moscato G, Mazzetti P, Lucenteforte E, Rosellini A, Cara A, Quaranta P, Mainardi V, Villa P,
 1242 Focosi D, Lanza M, Bianco I, Mazzoni A, Falcone M, Menichetti F, Maggi F, Lai M, Freer G,
 1243 Pistello M. 2021. Assessment of automated high-throughput serological assays for prediction
 1244 of high-titer SARS-CoV-2 neutralizing antibody. Journal of Clinical Virology Plus 1:100016.

- 1245 119. Jahrsdörfer B, Kroschel J, Ludwig C, Corman VM, Schwarz T, Körper S, Rojewski M, Lotfi R,
 1246 Weinstock C, Drosten C, Seifried E, Stamminger T, Groß HJ, Schrezenmeier H. 2021.
 1247 Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS 1248 CoV-2 Antibody Testing. J Infect Dis 223:796-801.
- 1249 120. Di Germanio C, Simmons G, Kelly K, Martinelli R, Darst O, Azimpouran M, Stone M, Hazegh K,
 1250 Grebe E, Zhang S, Ma P, Orzechowski M, Gomez JE, Livny J, Hung DT, Vassallo R, Busch MP,
 1251 Dumont LJ. 2021. SARS-CoV-2 Antibody persistence in COVID-19 convalescent plasma
 1252 donors: Dependency on assay format and applicability to serosurveillance. Transfusion
 1253 doi:10.1111/trf.16555:2021.03.24.21254260.
- 1254 121. Misset B, Hoste E, Donneau A-F, Grimaldi D, Meyfroidt G, Moutschen M, Compernolle V, 1255 Gothot A, Desmecht D, Garigliany M, Najdovski T, Laterre P-F. 2020. A multicenter 1256 randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with 1257 Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the 1258 CONFIDENT trial protocol. BMC Pulmonary Medicine 20:317.
- 1259 122. Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, Widdowson MA, 1260 Mortgat L, Duysburgh E, Desombere I, Jansens H, Van Esbroeck M, Ariën KK. 2021. 1261 Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in 1262 severe and mild COVID-19 cases using a Luminex bead-based assay. J Virol Methods 1263 288:114025.
- 123. Betrains A, Godinas L, Woei AJF, Rosseels W, Van Herck Y, Lorent N, Dierickx D, Compernolle
 V, Meyfroidt G, Vanderbeke L, Vergote V, Lagrou K, Verhamme P, Wauters J, Vermeersch P,
 Devos T, Maes P, Vanderschueren S. 2021. Convalescent plasma treatment of persistent
 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with
 lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J
 Haematol 192:1100-1105.
- 1270 124. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM, 1271 Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-1272 Fidouh N, Reusken C, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL. 2020. Severe 1273 Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis 26:1478-1488.
- 125. Amanat F, White KM, Miorin L, Strohmeier S, McMahon M, Meade P, Liu W-C, Albrecht RA, Simon V, Martinez-Sobrido L, Moran T, García-Sastre A, Krammer F. 2020. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. 58:e108.
- 1278 126. Walker GJ, Naing Z, Ospina Stella A, Yeang M, Caguicla J, Ramachandran V, Isaacs SR,
 1279 Agapiou D, Bull RA, Stelzer-Braid S, Daly J, Gosbell IB, Hoad VC, Irving DO, Pink JM, Turville S,
 1280 Kelleher AD, Rawlinson WD. 2021. SARS Coronavirus-2 Microneutralisation and Commercial
 1281 Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays. Viruses
 1282 13.
- 1283 127. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, Budylowski P, Dupuis 1284 AP, II, Girardin RC, Rathod B, Wang JH, Barrios-Rodiles M, Colwill K, McGeer AJ, Mubareka S, 1285 Gommerman JL, Durocher Y, Ostrowski M, McDonough KA, Drebot MA, Drews SJ, Rini JM, 1286 Gingras A-C. 2020. A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI 1287 Insight 5.
- 1288 128. De Santis G, Oliveira L, Garibaldi P, Almado C, Croda J, Arcanjo G, Oliveira E, Tonacio A, Langhi D, Bordin J, Gilio R, Palma L, Santos E, Haddad S, Prado B, Pontelli M, Gomes R, 1290 Miranda C, Martins M, Covas DA, E, Fonseca B, Calado R. 2021. High-dose convalescent plasma for the treatment of severe COVID-19:a multicenter randomized clinical trial. Int J 1292 Infect Dis.
- 1293 129. Oguntuyo KY, Stevens CS, Hung C-T, Ikegame S, Acklin JA, Kowdle SS, Carmichael JC, Chiu H-1294 p, Azarm KD, Haas GD, Amanat F, Klingler J, Baine I, Arinsburg S, Bandres JC, Siddiquey MN, 1295 Schilke RM, Woolard MD, Zhang H, Duty AJ, Kraus TA, Moran TM, Tortorella D, Lim JK,

- Gamarnik AV, Hioe CE, Zolla-Pazner S, Ivanov SS, Kamil JP, Krammer F, Lee B. 2020.

 Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera. mBio 12.
- 130. Anonymous. Wu, Fan and Wang, Aojie and Liu, Mei and Wang, Qimin and Chen, Jun and Xia, Shuai and Ling, Yun and Zhang, Yuling and Xun, Jingna and Lu, Lu and Jiang, Shibo and Lu, 1301 Hongzhou and Wen, Yumei and Huang, Jinghe, Neutralizing Antibody Responses to SARS-1302 CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications (3/28/2020). Available at SSRN: https://ssrn.com/abstract=3566211 or http://dx.doi.org/10.2139/ssrn.3566211.
- 1304 131. Beltrán-Pavez C, Riquelme-Barrios S, Oyarzún-Arrau A, Gaete-Argel A, González-Stegmaier R,
 1305 Cereceda-Solis K, Aguirre A, Travisany D, Palma-Vejares R, Barriga GP, Gaggero A, Martínez 1306 Valdebenito C, Corre NL, Ferrés M, Balcells ME, Fernandez J, Ramírez E, Villarroel F, Valiente 1307 Echeverría F, Soto-Rifo R. 2021. Insights into neutralizing antibody responses in individuals
 1308 exposed to SARS-CoV-2 in Chile. 7:eabe6855.
- 1309 132. Dieterle ME, Haslwanter D, Bortz RH, 3rd, Wirchnianski AS, Lasso G, Vergnolle O, Abbasi SA,
 1310 Fels JM, Laudermilch E, Florez C, Mengotto A, Kimmel D, Malonis RJ, Georgiev G, Quiroz J,
 1311 Barnhill J, Pirofski LA, Daily JP, Dye JM, Lai JR, Herbert AS, Chandran K, Jangra RK. 2020. A
 1312 Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated
 1313 Cell Entry and Its Inhibition. Cell Host Microbe 28:486-496.e6.
- 131. Rasheed AM, Fatak DF, Hashim HA, Maulood MF, Kabah KK, Almusawi YA, Abdulamir AS.
 1315 2020. The therapeutic potential of convalescent plasma therapy on treating critically-ill
 1316 COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med
 1317 28:357-366.
- 1318 134. Balcells ME, Rojas L, Le Corre N, Martínez-Valdebenito C, Ceballos ME, Ferrés M, Chang M, 1319 Vizcaya C, Mondaca S, Huete Á, Castro R, Sarmiento M, Villarroel L, Pizarro A, Ross P, 1320 Santander J, Lara B, Ferrada M, Vargas-Salas S, Beltrán-Pavez C, Soto-Rifo R, Valiente-1321 Echeverría F, Caglevic C, Mahave M, Selman C, Gazitúa R, Briones JL, Villarroel-Espindola F, 1322 Balmaceda C, Espinoza MA, Pereira J, Nervi B. 2020. Early Anti-SARS-CoV-2 Convalescent 1323 Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial. PLoS 1324 Medicine doi:10.1371/journal.pmed.1003415.
- 1325 Anonymous. National COVID19 Convalescent Plasma Project. Commentary from the COVID-135. 1326 19 Convalescent Plasma Project (CCPP19) Leadership Group on "Early Convalescent Plasma 1327 High-Risk Outpatients with Covid-19". Accessed for online 1328 https://ccpp19.org/news/review%20of%20NEJM%20US%20outpatient%20CP%20trial%208-1329 23.docx on August 25, 2021.
- 1330 136. Anonymous. March 2, 2021. NIH halts trial of COVID-19 convalescent plasma in emergency
 1331 department patients with mild symptoms. https://www.nih.gov/news-events/news-releases/nih-halts-trial-covid-19-convalescent-plasma-emergency-department-patients-mild-symptoms. Accessed
- 137. Beltran Gonzalez JL, Gonzalez Gamez M, Mendoza Enciso EA, Esparza Maldonado RJ, 1335 Hernandez Palacios D, Duenas Campos S, Ovalle Robles I, Macias Guzman MJ, Garcia Diaz AL, 1336 Gutierrez Pena CM, Reza Escalera AL, Tiscareno Gutierrez MT, Galvan Guerra E, Dorantes 1337 Morales MdR, Martinez Medina L, Monroy Colin VA, Arreola Guerra JM. 2021. Efficacy and 1338 safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 1339 patients. A controlled clinical trial. medRxiv [Preprint] doi:10.1101/2021.03.28.21254507 %J medRxiv:2021.03.28.21254507.
- 1341 138. Sekine L, Arns B, Fabro BR, Cipolatt MM, Machado RRG, Durigon EL, Parolo E, Pellegrini JAS,
 1342 Viana MV, Schwarz P, Lisboa TC, Dora JMS, Balsan AM, Schirmer FD, Franz JPM, da-Silveira
 1343 LM, Breunig RC, Petersen V, Sosnoski M, Mesquita NF, Volpato FCZ, Sganzerla D, Falavigna
 1344 M, Rosa RG, Zavascki AP. 2021. Convalescent plasma for COVID-19 in hospitalised patients:
 1345 an open-label, randomised clinical trial. Eur Respir J doi:10.1183/13993003.01471-2021.

- 1346 139. Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, Compernolle V,
 1347 Dauby N, Desmecht D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Moutschen M, Romano
 1348 M, Seyler L, Nevessignsky MT, Vandenberghe K, van Griensven J, Verbeke G, Vlieghe E,
 1349 Yombi JC, Liesenborghs L, Verhamme P, Meyfroidt G. 2020. A randomized, multicentre,
 1350 open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the
 1351 addition of convalescent plasma to the standard of care in patients hospitalized with COVID1352 19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 21:981.
- 1353 140. Jiang W, Li W, Xiong L, Wu Q, Wu J, He B, Shen J, Pang R, Luo T, Guo Y, Yang Y, Han Y, Dai W, 2hu P, Xia X. 2020. Clinical efficacy of convalescent plasma therapy on treating COVID-19 patients: Evidence from matched study and a meta-analysis. Clin Transl Med 10:e259.
- 1356 141. Pappa V, Bouchla A, Terpos E, Thomopoulos TP, Rosati M, Stellas D, Antoniadou A, Mentis A, 1357 Papageorgiou SG, Politou M, Kotanidou A, Kalomenidis I, Poulakou G, Jahaj E, Korompoki E, 1358 Grigoropoulou S, Hu X, Bear J, Karaliota S, Burns R, Pagoni M, Trontzas I, Grouzi E, 1359 Labropoulou S, Stamoulis K, Bamias A, Tsiodras S, Felber BK, Pavlakis GN, Dimopoulos MA. 1360 2021. A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe 1361 COVID-19- A Propensity Score-Matched Control Analysis. Microorganisms 9:806.
- 1362 142. Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ,
 1363 Chen J, Castillo B, Leveque C, Towers DM, Lavinder J, Gollihar JD, Cardona J, Ippolito GC,
 1364 Nissly RH, Bird IM, Greenawalt D, Rossi RM, Gontu A, Srinivasan S, Poojary IB, Cattadori IM,
 1365 Hudson PJ, Joselyn N, Prugar L, Huie K, Herbert A, Bernard DW, Dye J, Kapur V, Musser JM.
 1366 2020. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding
 1367 domain IgG correlate with virus neutralization. J Clin Invest 130:6728-6738.
- 1368 143. Tworek A, Jaroń K, Uszyńska-Kałuża B, Rydzewski A, Gil R, Deptała A, Franek E, Wójtowicz R, 1369 Życińska K, Walecka I, Cicha M, Wierzba W, Zaczyński A, Król ZJ, Rydzewska G. 2021. 1370 Convalescent plasma treatment is associated with lower mortality and better outcomes in 1371 high risk COVID-19 patients - propensity score matched case-control study. Int J Infect Dis 1372 105:209-215.
- 1373 144. Cristelli MP, Junior DML, Viana LA, de Andrade LGM, Martins SBS, Dreige YC, Bordim JO, 1374 Tedesco-Silva H, Medina-Pestana J. 2021. Efficacy of Convalescent Plasma to Treat Mild to 1375 Moderate COVID-19 in Kidney Transplant Patients: A Propensity Score Matching Analysis. 1376 Transplantation doi:10.1097/tp.000000000003962.
- 1377 145. Chauhan L, Pattee J, Ford J, Thomas C, Lesteberg K, Richards E, Loi M, Dumont LJ, Annen K, 1378 Berg M, Zirbes M, Miller A, Jenkins TC, Bennett TD, Monkowski D, Boxer RS, Beckham JD. 1379 2021. A Multi-center, Prospective, Observational-cohort controlled study of Clinical Outcomes following COVID-19 Convalescent plasma therapy in hospitalized COVID-19 patients. Clin Infect Dis doi:10.1093/cid/ciab834:ciab834.
- Acknowledgements: this manuscript is written in memory of Dr.Giuseppe De Donno, Director of the Pneumology Division at the Mantua Hospital, a pioneer in the field of CCP.

1385

Author biographies:

1388 Daniele Focosi



Dr. Focosi is a hematologist employed since 2009 as resident transfusion physician at the Pisa University Hospital. He has formerly been transplant immunologist and immunogeticist, quality assurance manager and production manager at the largest blood bank in Italy. He has received awards from the European Federation of Immunogenetics, the European Society of Organ Transplantation, and the Italian Society of Hematology. He has a Ph.D. degree in Clinical and Fundamental Virology, and a master degree in Clinical trials. He has authored 169 articles on topics ranging from emerging viral infections to new markers of immune compentence (including more than 50 and a SringerNature book on SARS-CoV-2 evolution), for a h-index of 30.

Massimo Franchini



Dr. Franchini specialized in Hematology (1995) at the University of Verona (Italy). He is currently Director of the Department of Hematology and Transfusion Medicine of the Hospital of Mantua (Italy). He is associate Editor of Seminars in Thrombosis and Hemostasis, Member of the Committee of the Italian Association of Hemophilia Centers (AICE) for the revision of the Italian Guidelines on the management of Hemophilia. He is a member of the Regional Hematology Network (REL, Lombardy Region) - subcommittee of Hemostasis, and served as consultant of the Italian Ministry of Health – National Blood Center (2016-2020). His field of scientific research is predominantly dedicated to hemostasis and thrombosis. His is currently studying the COVID-19 convalescent plasma, from biological validation to its clinical use. He has authored more than 650 publications for a h-index of 83.

Liise-anne Pirofski



Dr. Liise-anne Pirofski is a physician-scientist. Her research programs focus on immunity to encapsulated pathogens and antibody mediated immunity to infectious diseases. She is chief of the Division of Infectious Diseases and the Jacques and Selma Mitrani Chair in Biomedical Research at Albert Einstein College of Medicine and Montefiore Medical Center. She is a member of the American Association of Physicians and a fellow of the American Academy of Microbiology, American College


of Physicians, Infectious Diseases Society of America, and the American Association for the Advancement of Science. She is deeply devoted to biomedical education and mentoring for which she has received numerous accolades, including the American Society for Microbiology William A Hinton Award, and the Albert Einstein College of Medicine Faculty Mentoring Award, Harry Eagle Award for Outstanding Basic Science Teaching, and the Lifetime Achievement Award from the Albert Einstein College of Medicine Alumni Association.

Thierry Burnouf



Dr. Burnouf is a protein biochemist who has authored more than 280 publications in the field of therapeutic blood products for a h-index of 53. He has received the 2019 Award from the International Plasma Fractionation Association. His current research interest focuses on Platelet growth factors for regenerative medicine and cell therapy, Plasma fractionation, Viral inactivation technologies, and Blood biotechnology. He is the Secretary of the Working Party on Global Blood Safety, and the Treasurer of the Working Party on Cellular Therapies of the International Society of Blood Transfusion.

1434 Nigel Paneth




Dr. Paneth is a pediatrician and perinatal and child health epidemiologist with a particular interest in the causes and prevention of childhood neurodevelopmental handicap, especially cerebral palsy (CP). He was among the promotors of the US National COVID19 Convalescent Plasma Project (CCPP10). He is Emeritus University Distinguished Professor of Epidemiology and Biostatistics and Pediatricshas authored more than 320 publications for a h-index of 86.

Michael J. Joyner



Dr.Joyner has authored more than 535 publications for a h-index of 93. His laboratory is interested in how humans respond to various forms of physical and mental stress during activities such as exercise, hypoxia, standing up and blood loss. Dr. Joyner is leading a national program sponsored by the U.S. Government to coordinate the collection and distribution of COVID-19 convalescent plasma for the treatment of individuals with severe or life-threatening disease.

Arturo Casadevall



He is the chair of the Molecular Microbiology & Immunology, Bloomberg distinguished professor Alfred & Jill Sommer professor and chair professor. He has authored more than 900 PubMed-indexed articles for a h-index of 133. His research focuses on host defense mechanisms, how fungi cause disease, and in the development of antibody-based therapies for infectious diseases.